

September 29, 2020

CURRICULUM VITAE

NAME: **Barry Robert Davis**

OFFICE ADDRESS: The University of Texas School of Public Health
1200 Herman Pressler St. W-916
Houston, TX 77030
Phone: (713) 500-9515
FAX: (713) 500-9530
E-mail: barry.r.davis@uth.tmc.edu

EDUCATION:

1969-1973 B.S., Life Sciences
Massachusetts Institute of Technology
Cambridge, Massachusetts

1973-1977 M.D.
University of California, San Diego
School of Medicine
La Jolla, California

1977-1978 Internal Medicine Internship
Worcester City Hospital
University of Massachusetts Medical School
Worcester, Massachusetts

1978 Certification, National Board of Medical Examiners

1978-1982 Sc.M., Applied Mathematics
Ph.D., Applied Mathematics
Brown University
Providence, Rhode Island

1992 Diplomate, American Board of Preventive Medicine
Public Health and General Preventive Medicine

PROFESSIONAL POSITIONS:

- 2016-2017 Interim Chair, Department of Biostatistics, University of Texas School of Public Health (UTSPH), Houston, Texas
- 2008- Present Guy S. Parcel Chair in Public Health, UTSPH
- 2007-2008 James W. Rockwell Professor in Public Health, UTSPH
- 1992- Present Professor of Biostatistics, UTSPH
- 2003- Present Director, Coordinating Center for Clinical Trials (CCCT), a research unit of UTSPH, consisting of 40 faculty and staff to conduct the research listed under CURRENT AND PRIOR RESEARCH
- 2007- Present Director of Clinical Research Design, Texas Heart Institute (THI), Houston, Texas
- 1993- Present Research Scientist, Adult Cardiology, THI
- 2006-2007 Executive Director, Biostatistics, Amgen, Inc., Thousand Oaks, California
- 2003-2006 Director, Division of Biostatistics, UTSPH
- 2003-2006 Professor of Biostatistics, University of Texas M.D. Anderson Cancer Center (UTMDACC), Houston, Texas
- 2000-2003 Co-Director, CCCT, UTSPH
- 1998-2001 Convener of Biostatistics, UTSPH
- 1992-2003 Professor of Biomathematics, UTMDACC
- 1987-1992 Associate Professor of Biostatistics, UTSPH
- 1990-1992 Associate Professor of Biomathematics, UTMDACC
- 1983-2000 Deputy Director, CCCT, UTSPH
- 1983-1987 Assistant Professor of Biostatistics, UTSPH Public Health
- 1982-1983 Assistant Professor of Applied Mathematics and Medicine, Brown University, Providence, RI
- 1979-1982 Research Assistant, Division of Applied Mathematics, Brown University, Providence, RI
- 1978-1983 Ambulatory Care Physician, Truesdale Clinic, Fall River, Massachusetts

HONORS:

- University of California Regents Scholar, 1973-1977
- University Fellowship, Brown University, 1978-1979
- Dean's Teaching Excellence List, The University of Texas School of Public Health, 1988-1989
- Fellow, American Heart Association, Council on Epidemiology, 1990
- Fellow, American College of Preventive Medicine, 1992
- Outstanding Faculty Award, The University of Texas Health Science Center, 1992, 1993, 1994, 1995, 1996, 1997, 1998, 1999, 2003
- Who's Who in Science and Engineering, 1993
- Who's Who in the South and Southwest, 1994
- Peer Recognition for Outstanding Achievement in Sponsored Research, 1994
- ALLHAT Project - "Largest Contract Ever Received by UT - Houston"
- Fellow, American Statistical Association, 1996
- The University of Texas Health Science Center, Nationally Recognized Honors in Research, 1996, 2003

- The University of Texas Health Science Center, Nationally Recognized Honors in Service, 1997, 1999, 2001, 2002
- President, Society for Clinical Trials, 1999-2000
- Chair, Biometrics Section, American Statistical Association, 2003
- ALLHAT selected as one of “Top Ten Achievements for 2002” by American Heart Association
- ALLHAT findings in JAMA 12/18/2002 cited by Thomson-ISI Web of Science as “one of the most cited recent papers in the field of Clinical Medicine”
- Honorary member of the Chilean Society of Internal Medicine, 2003
- Special Recognition of ALLHAT by the University of Texas Health Science Center, September 2003
- Houston Mayoral Proclamation – September 19, 2003 – ALLHAT Clinical Trial Day
- UTHSC-Houston President’s Scholar Award for Research, 2004
- Fellow, Society for Clinical Trials, 2007
- James W. Rockwell Professor in Public Health, UTSPH, 2007
- Guy S. Parcel Chair in Public Health, UTSPH, 2008
- Fellow, American Association for the Advancement of Science, 2014
- Elected Member, International Statistical Institute, 2015
- Fellow, American Society of Hypertension, 2016

MEDICAL LICENSURE:

Texas, 1984-G6159

APPOINTMENTS:

Emerging Risk Factors Collaboration, 2013-
Virtual International Cardiovascular and Cognitive Trials Archive (VICCTA), 2013-
Trans-Cranial Doppler (TCD) with Transfusion Changing to Hydroxyurea (TWITCH)
Steering Committee, 2010-
Executive Committee, 2011
Operations Committee, 2010-
Publications Committee, 2013 –
FLuctuATion reduction with inSULin and GIp-1 Added together (FLAT-SUGAR)
Steering Committee, 2011-
Executive Committee, 2011-
Operations Committee, 2011-
Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)
Executive Committee, 1994-, (Chair, 2003-2007)
Steering Committee, 1994-
Endpoints Committee, 1994-2003
Recruitment and Eligibility Committee, 1994-1997
Publications and Ancillary Studies Committee, 1994-
Quality Control Committee (Chair), 1994 -2003
Dissemination Committee, 2002-2010
Genetics of Hypertension Associated Treatments (Gen HAT),

Steering Committee, 1999-
Systolic Hypertension in the Elderly Program (SHEP)
 Endpoints and Toxicity Subcommittee, 1984-1992
 Scientific Review Subcommittee, 1984-1992
 Drug Selection Working Group, 1984-1985
 Publications and Presentations, 1991-1996
Trial of Antihypertensive Interventions and Management (TAIM)
 Design and Management Subcommittee, 1985-1988
Hypertension and Detection Follow-up Program (HDFP)
 HDFP Publications Committee, 1986-1992
Survival and Ventricular Enlargement Trial (SAVE)
 Mortality and Endpoint Subcommittee, 1986-1992
Continuation of Trial of Antihypertensive Interventions and Management (COTAIM)
 Chair, Executive Committee, 1988-1995
 Design and Management Subcommittee, 1988-1995
 Cost Benefit Subcommittee, 1988-1995
Cholesterol and Recurrent Events Trial (CARE)
 Endpoints Committee, 1989-1993
Vioxx Gastrointestinal Outcomes Research Study (VIGOR)
 Steering Committee, 1999-2002
Prevention of Restenosis with Tranilast and Its Outcomes: A Placebo-Controlled Trial (PRESTO)
 Steering Committee, 1999-2002
The Prospective Pravastatin Pooling (PPP) Project, 1999-2006
The World Health Organization-International Society of Hypertension Blood Pressure Lowering
 Treatment Trialists' Collaboration, 1999- , Member of Steering Committee, 2014-
Cholesterol Treatment Trialists' Collaboration, 1999-
International Advisory Committee, Aspirin in Reducing Events in the Elderly (ASPREE), 2003-
The University of Texas School of Public Health
 Committee for Faculty Affairs, 1986-1988
 AIDS Working Group, 1987-1989
 Chair, Faculty Merit Review Committee, 1988-1989
 Search Committee for Occupational Health Physician Faculty Member, 1988-1990
 Biometry Admissions Committee, 1988-2003
 Biometry Faculty Search Committees, 1988-1989, 1992-1993
 Biometry Brochure Committee, 1988
 Chair, Strategic Planning Committee, 1989-1990
 Faculty Policy Committee, 1989-1990
 Epidemiology Faculty Search Committee, 1991- 1992, 1996-1997
 Convener, Disease Control Module, 1995-1997
 Academic Affairs Committee, 1995-1998
 Faculty Affairs Committee (FAC), 1998-2001; Chair, 2000-2001
 Lorne Baine Professorship Search Committee, 1998-1999
 Faculty Peer Review Committee, 2001, 2002 (Co-Chair)
 Division Directors Committee, 2003-2006

Executive Council, 2003-2006.
Research Council, 2007-
Biostatistics Division Director Search Committee, 2007-2008
Biostatistics/Coordinating Center Faculty Search Committee (Chair), 2008-
Biostatistics Faculty Search Committee, 2008-
The University of Texas Health Science Center
Scientific Review Committee, 1987-1990
Internal Review Committee for PEW Scholars Program, 1991
Search Committee for Dean of UT School of Public Health, 2004
The University of Texas Health Science Center
Planning Committee for Burroughs Wellcome Foundation RFP, 2008.
Clinical Trials Comm. for UT System for Prop 15-related Cancer Institute funding, 2008
President's Scholar for Research and Teaching Selection Committee - 2005, 2009, 2010,
2011, 2012, 2013, 2014, 2015
Baylor College of Medicine
Research Subcommittee, Program in Aging, 1987-1990
American Association for the Advancement of Science, Member, 1980-present
American Heart Association, Council on Epidemiology
Chair, Committee on Criteria and Methods, 1988-1991; Member, 1987-1991
Executive Committee, 1988-1991
American Statistical Association
Membership Committee, 1988-1994
Council on Sections Representative, Biometrics Section (Elected Position), 1992-1995
Biometrics Section Executive Committee, 1992-1995, 2001-2004
Nominations Committee, 1993-1995
ASA Representative to ENAR, Member of RECOM, 1995-1997
Byar Awards Committee, 2001, 2002, 2003 (Chair)
Chair, Biometrics Section (Elected Position), 2003
Society for Clinical Trials
DMC (Data Monitoring Committee) Initiative, 2020-
Training Subcommittee, 2020-
Program Committee 1989, 1996, 1997 (Chair), 1998
Board of Directors (Elected Position), 1993-1997
Executive Committee, 1998-2000
Development Committee, 1999-2000
Education Committee, 1999-2000
Finance Committee, 1999-2000
Membership Committee, 1999-2000
Nominating Committee, 1999-2000
Publications Committee, 1999-2000
Student Scholarship Committee, 1999-2000
Policy Committee, 2000, 200, 200, 2003(Chair), 2004, 2005
President-Elect, 1998-1999
President (Elected Position), 1999-2000

Past President 2000-2001
Fellows Committee, 2008, 2009 (Chair), 2010 (Chair), 2011

International Biometric Society (IBS)
Regional Advisory Board, Eastern North American Region (ENAR), 1989-1991
ENAR in Houston 1991, Local Arrangements Committee, 1988-1989
Liaison to the 1991 ENAR Program Committee
Institute of Mathematical Statistics (IMS), Assistant Secretary
Regional Committee [RECOM] (Elected Position), Eastern North American Region (ENAR), 1996-1998
IBS Council (Elected Position), Member of RECOM, 2000-2002
Student Awards Review Committee, 2001
Nominations Committee, 2002-2003
Presidential Nominee, 2005, 2008

International Society for Biopharmaceutical Statistics, Advisory Committee, 2006-2007

National Eye Institute
Special Subcommittee on the Future of Clinical Trials Methodology, 1990
Glaucoma Surgical Outcomes Study Advisory Committee, 2000-2002

National Institute of Allergy and Infectious Diseases
Epidemiology and Technology Transfer Subcommittee of the AIDS Research Review Committee, 1990-1994

National Institute of Health Reviewers Reserve, 1994-1998

Veterans Affairs Cooperative Studies Program - Cooperative Studies Scientific Evaluation Committee (CSSEC) formerly Cooperative Studies Merit Review Board (CSSMRB), 2005-2018
(Acting Chair - 2011, 2012)

National Heart, Lung, and Blood Institute (NHLBI) - Strategic Plan for Cardiovascular Disease, Level 1 Working Group on Clinical Trials Methodology, one of 12 designated thematic areas - 2006

Texas Heart Institute
Director of Clinical Research Design, 2007-
Research Committee, 2008 –

ARTERY (tAilored dRug Titration through analytic intElligence: an interventional study)
Steering Committee - an NHLBI-funded clinical trial at UCSF, 2017-

Alzheimer's Association - Protect brain health through lifestyle Intervention to Reduce risk in the U.S. (U.S. POINTER) Scientific Advisory Board, 2017-

National Heart, Lung, and Blood Institute (NHLBI) - Collaborating Network (CCTRN Network) of Networks for Evaluating COVID-19 and Therapeutic Strategies (CONNECTs), 2020-
Statistics and Data Analysis Committee, 2020-

DATA AND SAFETY MONITORING BOARD APPOINTMENTS:

Texas Children's Hospital Policy Advisory Committee
Alternate Day Steroids to Promote Growth in Children with Crohn's Disease, 1990-94

VA Cooperative Studies Operations Committee Data Monitoring Boards
Study #300, Detection & Treatment of Influenza A in High Risk Ambul. Pts, 1986-1990

Study #363, The VA HDL Intervention Trial (HIT), 1991-1997
National, Heart, Lung, and Blood Institute Data and Safety Monitoring Committees
Trial of Nonpharmacologic Interventions in the Elderly (TONE), 1992-1995
National Growth and Health Study (NGHS), 1992-1998
Magnesium in Coronary Arteries (MAGIC), 1998-2002
OmniHeart (Dietary Treatment of Hypertension), 2002-2005
Home Automatic External Defibrillator Trial (HAT), 2002-2007
OmniCarb (Dietary Treatment of Hypertension), 2007- 2010
Catheter Ablation vs Antiarrhythmic Drug Therapy for AFib Trial (CABANA), 2009-2018.
Physician/Pharmacist Collaborative Management for Blood Pressure Control Trial (CAPTION), Chair, 2009-2014
Systolic Blood Pressure Intervention Trial (SPRINT), 2010-2018.
MEDication Focused Outpatient Care for Underutilization of Secondary Prevention (MedFocus), Chair, 2014-2018
National Cancer Institute Data Monitoring Committee
Intergroup Rhabdomyosarcoma Study, 1993-1998
National Eye Institute Data Monitoring Committees
Ocular Hypertension Treatment Study (OHTS), Chair, 1993-2009
Randomized Trial for Retinitis Pigmentosa, 1995-2003
Pediatric Eye Disease investigative Group (PEDIG), 1997-
Studies of Ocular Complications of AIDS (SOCA), 1998-2013
National Institute of Dental Research Data Monitoring Committee
Children's Amalgam Trial (CAT), 1997-2005
National Institute of Diabetes and Digestive and Kidney Diseases Data Monitoring Committee
Action for Health in Diabetes (Look AHEAD), 2002 –2011
Epidemiology of Diabetes Interventions and Complications (EDIC) 2011 -
National Center for Complementary and Alternative Medicine (NCCAM).
Trial to Assess Chelation Therapy (TACT) 2003-2012
National Institute of Neurological Disorders and Stroke (NINDS)
A Randomized Multicenter Clinical Trial of Unruptured Brain AVMs (ARUBA), 2006-2013
National Institute on Alcohol Abuse and Alcoholism
The Moderate Alcohol and Cardiovascular Health Trial (MACH15) [and Protocol Review Committee], 2017-2018.
National Aeronautics and Space Administration
Prebreathe Reduction Protocol and Related Research, 2000-2001
G.D. Searle, Inc. – Eval. of Xemilofibrin in Controlling Thrombotic Events (EXCITE), 1997-1999
Eli Lilly and Company -Monoxidine for Arterial Pressure (MAP), 1997-1999
Merck, Inc. - MEDAL/EDGE1/EDGE2 (Cox-2 inhibitors/Cardiovascular Disease), 2002-2005
Miravant - Photopoint Study in Age-Related Macular Degeneration, 1998-2002
Pfizer - ALLIANCE - Trial of Atorvastatin vs. Usual Care, 1998-2003
Takeda Pharmaceuticals - CHICAGO/PERISCOPE (Pioglitazone trials), 2003-2006
Takeda Pharmaceuticals - Bone Density Trial, 2008-2011
GlaxoSmithKline (Co-Chair) – Phase II LpLA2 inhibitor trial, 2005-2006

Biomarin (Chair) – Antihypertensive agent, 2005-2006.
Procter and Gamble Pharmaceuticals, Testosterone Patch Trial, 2006.
University of Texas, Houston – Center for Clinical and Translational Sciences DSMB, 2008-
Baylor College of Medicine, Cluster randomized controlled trial of pay for performance for
hypertension treatment, Oversight Committee, 2008-2013
Amgen, Pegfilgrastim Trial in Metastatic Colorectal Cancer, 2009-2012
Merck, Large LABA-Safety Trial, 2011-2017
Amgen 145 Program, 2012-
Sunovion, Lurasidone Program, 2012-2014
Regeneron, REGN475 Program, 2015-
Amgen 334 Program, 2015-
EIDOS, AG10 Program, 2018-

FOOD AND DRUG ADMINISTRATION EXPERIENCE:

Coordinating Center for SAVE and CARE trials (listed under CURRENT AND PRIOR RESEARCH) including work with Bristol-Myers Squibb to obtain new indications for captopril and pravachol, respectively.
Expert for Merck, Inc. for rotavirus vaccine at FDA Vaccines and Related Biological Products Advisory Committee, 2001.
Expert testimony for FDA Cardiorenal Advisory Committee for the ALLHAT Study regarding doxazosin, 2001
Guest Expert Panel Member- FDA Anti-infectives Drug Advisory Committee, 2001.
Amgen – various Phase 2,3 trials including preparation and attendance at Oncology Drug Advisory Committee and Cardio-Renal Drug Advisory Committee, 2006-2007.
Member, Cardiovascular and Renal Drugs Advisory Committee, 12/2013-7/2020

CONSULTANT EXPERIENCE:

Providence VA, Providence, RI –Dept. Lab Services, Neurology Service Research Laboratory
Rhode Island Hospital, Providence, Rhode Island -The Cardiology Department
Baylor College of Medicine, Houston, Texas
Departments of Obstetrics and Gynecology, Endocrinology
Pediatric Gastroenterology Collaborative Research Group
The Stehlin Foundation for Cancer Research
The University of Texas Medical School, Houston, Texas - Department of Cardiology
Houston Department of Health and Human Services
Texas Task Force on AIDS
St. Joseph's Hospital, Houston, Texas - Departments of Microvascular Surgery, Plastic Surgery
Medical College of Georgia, Augusta, Georgia
Cardiac Pacemakers, Inc.
UAW-Ford National Joint Committee on Health and Safety
Review Committees for NHLBI, NEI, NIDDK, NIAMS, NIAID
Bristol-Myers Squibb
Krug Life Sciences

Barry R. Davis
September 29, 2020
Page 9

National Aeronautics and Space Administration
G. D. Searle, Inc.
Bayer, Inc.
Merck, Inc.
Westat
SmithKline Beecham Pharmaceuticals
Eli Lilly and Company
Microsoft
Metrix Communications
Miravant
Parke-Davis
Pfizer, Inc.
Canadian Auto Workers Union
Universities Space Research Association
TAP Pharmaceutical Products, Inc.
GlaxoSmithKline
Amgen
Sunovion
Regeneron

PEER REVIEW ACTIVITIES:

Journals:

<i>AHFS Drug Information – Essentials Monograph</i>	<i>Controlled Clinical Trials</i>
<i>American Journal of Epidemiology</i>	<i>Current Cont. Trials in CV Medicine</i>
<i>American Journal of Hypertension</i>	<i>CVD Prevention</i>
<i>American Journal of Kidney Disease</i>	<i>Journal of American Geriatric Society</i>
<i>American Journal of Medicine</i>	<i>Journal of American Statistical Association</i>
<i>American Journal of Public Health</i>	<i>Journal of General Internal Medicine</i>
<i>Annals of Epidemiology</i>	<i>Journal of the National Cancer Institute</i>
<i>Archives of Ophthalmology</i>	<i>The Lancet</i>
<i>Biometrics</i>	<i>The Medical Letter</i>
<i>Chronobiology International</i>	<i>New England Journal of Medicine</i>
<i>Circulation</i>	<i>Preventive Medicine</i>
<i>Communications in Statistics</i>	<i>Statistics in Medicine</i>

Editorial Positions:

<i>Journal of American Statistical Association</i>	Assistant Editor, Special Biopharmaceutical Section Edition, 1990
<i>Controlled Clinical Trials</i>	Associate Editor, 1999-2003
<i>Circulation</i>	Statistical Reviewer, 2008 –
<i>Journal of the Society for Clinical Trials</i>	Associate Editor, 2008–
<i>Trials (Biomed Central),</i>	Associate Editor, 2008–
<i>Texas Heart Institute Journal</i>	Statistical Reviewer, 2008-
<i>Progress in Cardiovascular Diseases –</i>	Guest Editor (with Barbara Tilley), 2012
<i>Secondary Analyses in Cardiovascular Clinical</i>	
<i>Trials – Statistical and Other Considerations</i>	

Books:

Wiley-Interscience

Clinical Trials – A Methodological Perspective
Encyclopedia Of Clinical Trials

National Heart, Lung, and Blood Institute

Joint National Committee Hypertension Report (VIII), 2013

Funding Agencies (Various Review Committees since 1984):

National Institutes of Health - Div. of Research Grants and Epidemiology Study Section

National Heart, Lung, and Blood Institute.

National Institute of Allergy and Infectious Diseases.

National Institute of Arthritis and Musculoskeletal Diseases.

National Institute of Diabetes and Digestive and Kidney Diseases.

National Eye Institute

National Institute on Aging

National Institute of Craniofacial and Dental Research

Veterans Administration Cooperative Studies Program

Cooperatives Studies Scientific Evaluation Committee, 2004-

PROFESSIONAL ORGANIZATIONS:

American Association for the Advancement of Science--Fellow

American Heart Association Council on Epidemiology--Fellow

American College of Preventive Medicine--Fellow

American Statistical Association--Fellow

Houston Area Chapter

Chair, Biometrics Section, 2003

American Society of Hypertension – Fellow

International Biometric Society

Institute of Mathematical Statistics

Sigma Xi--elected member

Society for Clinical Trials--President, 1999-2000, Fellow

CURRENT GRANTS/CONTRACTS:

1. Principal Investigator and Director (2019-2020), Data Coordinating Center for Cell-Based Therapy for Cardiovascular Research Network (CCTRN)—A network of clinical centers and a coordinating center to conduct phase I and II collaborative trials of emerging cell based treatments of cardiovascular disease. NHLBI Cooperative Agreement-2UM1HL087318-06; 2012-2019 (\$63,000,000).
2. Principal Investigator and Director, Data Coordinating Center for Autologous Cardiac Stem Cell Injection in Patients with Hypoplastic Left Heart Syndrome (CHILD). The CHILD study is assessing the safety, feasibility, and efficacy of intramyocardial delivery of c-kit⁺ cells in patients with hypoplastic left heart syndrome under 6 months of age. Sponsored by the Marcus Foundation Inc.; 2019-2021 (\$609,279).
3. Principal Investigator, Coordinating Center Study Ancillary to Antihypertensive and Lipid Lowering Heart Attack Trial (ALLHAT) - Sustained Blood Pressure Control and Progression of Multimorbidity in ALLHAT NHLBI R01 (Subcontract from Duke University. 2016-2020. (\$316,284).
4. Co-Investigator, Coordinating Center Study Ancillary to Antihypertensive and Lipid Lowering Heart Attack Trial (ALLHAT) - Long-term Benefits & Harms of Antihypertensive Drugs in the Elderly: Up to 22-year Follow-Up of ALLHAT Trial Participants. Xianglin Du, PI. NIA R01. 2018-2022 (\$1,324,000).
5. Co-Investigator, Coordinating Center Study Ancillary to Antihypertensive and Lipid Lowering Heart Attack Trial (ALLHAT). Blood pressure control and antihypertensive drugs in ALLHAT trial participants and the risk of Alzheimers disease and related dementias - Xianglin Du, PI. NIA R01 Supplement.2020-2021 (\$299,245).
6. Principal Investigator, Data Coordinating Center, A Phase IIB Multicenter Study of the Comparative Efficacy and Safety of Transendocardial Injection of MSC in Patients with Non-Ischemic Dilated Cardiomyopathy . A phase Iib, randomized, double-blinded, placebo-controlled trial of allo-MSCs versus placebo administered via the Biosense Webster MyoStar NOGA Injection Catheter System tested in a total of 136 patients whose primary aim is to establish a genetic component to patient responses. Subcontract to University of Miami. DOD 2020-2024. (\$5,206,511)
7. Principal Investigator, Data Coordinating Center for Multi-Site Investigator-Initiated Clinical Trials -Allogeneic Human Mesenchymal Stem Cell (MSC) Injection in Patients with Hypoplastic Left Heart Syndrome: a Phase Iib Clinical Trial (ELPIS). NHLBI U24 2020-2025 (\$1,853,979)

PENDING GRANTS/ CONTRACTS

1. Principal Investigator, Data Coordinating Center for Multi-Site Investigator-Initiated Clinical Trials - Novel indication Toward a Consensus for Hydroxyurea (NiTCH): A multi-center double-blinded placebo-controlled Phase III clinical trial of hydroxyurea for children and adults with HbSC disease. NHLBI, 2019-2024 (\$4,329,341)
2. Principal Investigator, Data Coordinating Center for a randomized, controlled, double-blind phase II clinical trial of allogeneic mesenchymal stromal cells for treatment of COVID-19 patients with elevated troponin and mild respiratory impairment. Subcontract to University of Miami DOD 2020-2023 (\$2,367,075)

PAST GRANTS/CONTRACTS

1. Principal Investigator for Training for UTSPH Faculty and for Curriculum in Clinical Trials - Methods Training in Patient-Centered Cancer Outcomes Research. AHRQ R25 (Subcontract from MD Anderson Cancer Center). 2014-2019. (\$175,000)
2. Principal Investigator, Coordinating Center Study Ancillary to ALLHAT. Heart: Adding memory to Reasoning: Machine Learning Tailored Drug Titration. Optima Integrated Health. 2018-2019 (\$27,000)
3. Principal Investigator. Legacy Effects of Baseline Blood Pressure 'Treatment Naivety' in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack. NIH. 2018 (\$25,000)
4. Principal Investigator Improved characterization of postural blood pressure change in older adults. Beth Israel Deaconess. 2018 (\$15,000)
5. Principal Investigator and Director, Clinical Trials Center for "Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial" (ALLHAT)- A clinical trial in 623 centers to compare the effectiveness of four antihypertensive agents in reducing the incidence of coronary heart disease in 42,418 patients 55 years and older with diastolic and/or systolic hypertension. A second nested clinical trial will test the effectiveness of an HMG-CoA reductase inhibitor in reducing the incidence of all-cause mortality in 10,362 of these patients. NHLBI Contract. 1993-2011. (\$101,876,365); Phase 3: Continuation and Outreach - 2011-2016 (\$5,000,000).
6. Principal Investigator and Director, Coordinating Center for "FLuctuATion reduction with inSulin and GIp-1 Added together" (FLAT-SUGAR) -- A pilot clinical trial designed to compare whether glycemic variability can be reduced in diabetic patients on basal insulin with the addition of the GLP-1 analogue, exenatide, compared with the addition of prandial insulin (insulin glulisine). Sanofi-Aventis grant (Subcontract from University of Washington, Seattle) . 2011-2016. (\$852,527).

7. Principal Investigator and Director, Coordinating Center for "Trans-Cranial Doppler (TCD) With Transfusions Changing to Hydroxyurea" (TWiTCH) --: A Phase III randomized clinical trial to compare standard therapy (erythrocyte transfusions) with alternative therapy (hydroxyurea) for the maintenance of lowered TCD velocities in pediatric subjects with sickle cell anemia and abnormal pre-treatment TCD velocities. NHLBI R01. 2010-2015. (\$3,877,396).
8. Principal Investigator, Coordinating Center Study Ancillary to ALLHAT - Visit to Visit Variability of Blood Pressure and CVD and Renal Outcomes. NHLBI R01 (Subcontract from University of Alabama, Birmingham). 2012-2015. (\$274,815)
9. Principal Investigator and Director, "Improving Blood Pressure in the Community: A Joint Project of the National High Blood Pressure Education Program and Antihypertensive and Lipid Lowering Heart Attack Trial Dissemination Plan" – A dissemination project of ALLHAT, NHLBI, 2004-2007. (\$3,721,028).
10. Principal Investigator and Director, Clinical Trials Center for "Genetics of Hypertension Associated Treatments" (GENHAT)-- A prospective study to examine the association between selected hypertensive genes and coronary heart diseases modified by the type of antihypertensive treatment. GENHAT is an ancillary study of ALLHAT (see above). NHLBI. 1999- 2006.(\$1,474,101); Renewal (Co-I) - 2007-2012 (\$1,262,250).
11. Principal Investigator and Director, Training Grant in Biostatistics at UTSPH. -- A pre-doctoral research training program in biostatistics with emphasis on multi-disciplinary education, especially in clinical trials and genetics. NIGMS. 2006 (\$ 887,920).
12. Principal Investigator and Director, Data Coordinating Center for Cell-Based Therapy for Cardiovascular Research Network (CCTRN)—A network of clinical centers and a coordinating center to conduct phase I and II collaborative trials of emerging cell based treatments of cardiovascular disease. NHLBI. (original PI) 2006 (\$17,882,096).
13. Principal Investigator – Subcontract to “The Enigma of Placebo Adherence and Health Outcomes” for SHEP Placebo Adherence Study - NHLBI 2006. (\$55,628).
14. Principal Investigator and Director, Clinical Trials Center for "Genetics of Angioedema" (AngioGEN)-- A genetics outcome study to investigate the causes of angioedema. AngioGEN is an ancillary study of GENHAT (see above). Bristol-Myers. 2001-2003. (\$124,412).
15. Principal Investigator and Director, Coordinating Center "Continuation of Trial of Antihypertensive Interventions and Management" (COTAIM)--A continuation of the TAIM (see below) to study the long-term effects of dietary and pharmacologic treatment of mild hypertension. NHLBI. 1988-1995. (\$2,201,190).
16. Co-investigator and Deputy Director, Coordinating Center, "Systolic Hypertension in the Elderly Program" (SHEP)--A clinical trial in 16 centers to test the effectiveness of antihypertensive treatment in reducing the combined incidence of fatal and nonfatal stroke in 4736 elderly patients with isolated systolic hypertension. NHLBI. 1984-1995.(\$9,003,630).

17. Co-investigator and Deputy Director, Coordinating Center, "Hypertension Detection and Follow-up Program" (HDFP)--A clinical trial in 14 centers which investigated the differences in mortality and selected morbidity between 10,940 participants randomly allocated to an intensive hypertension control program and persons referred back to the regular medical care system. NHLBI. 1983-1992.(\$18,059,234).
18. Co-investigator, Coordinating Center, "Multicenter Trial of Cryotherapy for Retinopathy of Prematurity" (CRYO-ROP)--A randomized, multicenter trial in 24 centers to determine the safety and efficacy of cryotherapy of the retina in the treatment of retinopathy of prematurity in 291 infants. NEI. 1985-2001. (\$4,534,242).
19. Co-investigator, Coordinating Center, "Survival and Ventricular Enlargement--The Captopril Study" (SAVE)--A clinical trial in 40 centers to test the effectiveness of captopril in reducing total mortality and/or ventricular enlargement in 2231 post-myocardial infarction patients. Bristol-Myers-Squibb, Inc 1986-1994. (\$1,959,014).
20. Co-investigator, (Principal Investigator 2000-2003) Coordinating Center, "Cholesterol and Recurrent Events" (CARE)--A clinical trial in 80 centers to test the effectiveness of pravastatin in reducing cardiovascular events in 4000 post-myocardial infarction patients. Bristol-Myers-Squibb, Inc. 1988-2003. (\$4,319,394).
21. Co-investigator, "Corpus Christi Heart Project" (CCHP)--A surveillance study of MI incidence in a Hispanic and Anglo population. NHLBI. 1988-1992.
22. Co-investigator and Deputy Director, Coordinating Center, the "Trial of Antihypertensive Interventions and Management" (TAIM)--A 3-center study of the effectiveness of dietary and pharmacological measures in treating 878 mild hypertensives. NHLBI; 1984-1988. (\$1,058,316).
23. Co-investigator, Coordinating Center, "Beta-Blocker Heart Attack Trial" (BHAT)--A randomized double-blind clinical trial designed to test the effectiveness of propranolol in reducing mortality in 3837 post-myocardial infarction patients in 31 centers. NHLBI; 1983-1987.(\$4, 208,443).
24. Co-investigator, "An Open-Label Six-Month Evaluation of Safety of Proquazone Compared to Sulindac, Ibuprofen and Naproxen in Patients with Rheumatoid Arthritis or Osteoarthritis." An open-label randomized design study to compare the safety of non-steroidal anti-inflammatory drugs with particular reference to alternatives in standard routine liver and/or kidney function tests. Sandoz, Inc., 1983-1984.

GRANTS/CONTRACTS (NOT FUNDED)

1. Principal Investigator, Data Coordinating Center for Multi-Site Investigator-Initiated Clinical Trials - Single or repeated intravenous administration of umbilical cord mesenchymal stromal cells in ischemic cardiomyopathy (CATO). NHLBI, 2019-2024 (\$3,324,270)
2. Principal Investigator, Data Coordinating Center for Multi-Site Investigator-Initiated Clinical Trials - A Phase IIB, randomized, placebo-controlled, multicenter study of the comparative

efficacy and safety of transendocardial injection of allogeneic mesenchymal stem cells in patients with non-ischemic dilated cardiomyopathy (DCM-II). NHLBI, 2019-2024 (\$4,585,416)

3. Principal Investigator, Subcontract to Oregon Health Sciences University. Electrophysiological Substrate of Arrhythmias: ECGome Consortium NHLBI R01. 2019-2023 (\$431,200)
4. Principal Investigator and Director, Coordinating Center for "Prevention of Cardiovascular Disease in Diabetic Patients" (PCDD), now known as the ACCORD trial. NHLBI. 1999-2009. (\$37,562,893).
5. Principal Investigator and Director, Coordinating Center for "A Trial of Diastolic Heart Failure with an Aldosterone Antagonist", now known as TOPCAT. NHLBI 2004-2009. (\$59,783,000).
6. Principal Investigator and Director, Coordinating Center for "Hispanic Health Studies Network", now known as the Hispanic Community Health Study. NHLBI. 2006-2012. (\$34,382,000).
7. Principal Investigator and Director, Coordinating Center for "Systolic Blood Pressure Intervention Trial" (SPRINT) -- A clinical trial in 200 centers to test effectiveness of intensive versus standard lowering of systolic blood pressure in reducing cardiovascular disease risk in 7500 patients 55+ years with systolic hypertension. NHLBI. 2009-2018. (\$36,636,311).
8. Principal Investigator and Director, Program Project Grant – Biomarkers & Genes & Outcomes & Treatment – A project to utilizing the resources of ALLHAT to assess what are the biomarker, genetic, and clinical factors associated with clinical outcomes of hypertension and are these associations modified by type of treatment? NHLBI. 2010-2015 (\$8,821,388).
9. (Multiple) Principal Investigator. Definitive Phase III Clinical Trial Planning Grant (R34) Multicenter Trial for Benign Paroxysmal Positional Vertigo. NIDCD. 2011-2012 (\$427,728). Resubmission 2012-2013 (\$436,250).
10. Principal Investigator and Director, Coordinating Center for "Bevacizumab Blockade of VEGF for the Treatment of Retinopathy of Prematurity (BLOCK-ROP)" – A randomized, multicenter trial to determine the safety and efficacy of bevacizumab versus laser therapy in the treatment of retinopathy of prematurity in infants. NEI. 2012-2017 (\$15,636,034).
11. Principal Investigator, Coordinating Center Study Ancillary to ALLHAT- Long-term Outcomes in Older Patients with CKD. NIDDK (Subcontract from Case Western Reserve University). 2012-2016 (\$459,673).\
12. Principal Investigator, New Analyses for the ALLHAT. NHLBI. 2016-2021. (\$3,837,085)
13. Principal Investigator, Precision Medicine Initiative (PMI) Enrollment Center. The national PMI cohort will ultimately consist of more than one million individuals who have provided broad consent to participate in a long-term longitudinal research study to identify and understand the factors (genetic, environmental and socio-economic) contributing to individual health and disease. The University of Texas Health Science Center (UTHealth) and Baylor

College of Medicine (BCM) partnered to annually recruit from an integrated HPO network more than 35,000 ethnically and economically diverse individuals per year (10,000 in the first year) into the national PMI cohort. NIH. 2016-2021. (\$40,661,899).

14. Principal Investigator, Precision Medicine Initiative (PMI) Enrollment Center. Resubmission. NIH. 2016-2017. (\$4,000,000).
15. Principal Investigator, Environmental Influences on Child Health Outcomes (ECHO) Coordinating Center. The overall goal of the ECHO program is to investigate the effect of prenatal, perinatal and postnatal environmental exposures on pediatric health outcomes with high public health impact. To achieve this objective, three institutions, University of Texas Health Science Center at Houston (UTHealth), Baylor College of Medicine (BCOM), and Rice University, located in the world's largest medical complex—Texas Medical Center (TMC), joined together to establish the ECHO Coordinating Center. NIH 2016-2023. (\$103,704,509).
16. Principal Investigator, New CHD and Mortality Analyses for the ALLHAT. NHLBI. 2017-2022 (\$3,527,528).
17. Principal Investigator, Subcontract to Oregon Health Sciences University ALLHAT Sudden Cardiac Death Study. NHLBI. 2017-2021 (\$818,779), Resubmission 2018-2022 (\$655,740).
18. Principal Investigator, Subgroup Identification in ALLHAT. NHLBI. 2017-2022. (\$3,375,165). Resubmission. NHLBI. 2018-2022. (\$2,464,556)
19. Principal Investigator, Tight Blood Pressure Control and Cardiovascular Outcomes in Hypertensive Patients NHLBI. 2016-2022. (\$2,821,915). Resubmission. NHLBI. 2019-2023. (\$1,712,663)
20. Principal Investigator, Regenerative Medicine Innovation Catalyst Clinical Research Development and Data Hub NIH. 2018-2024. (\$6,110,852)

COURSES TAUGHT:

- General Biostatistics
- Statistical Methods in Epidemiology
- Logistic Regression
- Survival Analysis
- Decision Theory
- Infectious Disease Epidemiology
- Statistical Methods in Clinical Trials

LECTURER IN:

- Natural History of Disease
- Overview of AIDS
- Statistics for Medical Researchers

PUBLICATIONS:

1. **Davis BR:** Nonparametric prediction analysis for binary data. *Communications in Statistics* 13(9):1161-1175, 1984.
2. **Davis BR:** An associative, hierarchical self-organizing system. *IEEE Transactions on Systems, Man and Cybernetics* 15(4):570-579, 1985.
3. **The HDFP Cooperative Group:** Mortality findings for stepped-care and referred-care participants in the Hypertension Detection and Follow-up Program, stratified by other risk factors. *Preventive Medicine* 14:312-335, 1985.
4. **Davis BR, Slymen DJ, Cooper C, Mutchler L:** A distributed data processing system in a multicenter clinical trial. *American Statistical Association 1985 Proceedings of the Statistical Computing Section 89-96, 1985.* (Refereed paper).
5. **Davis BR, Ford CE, Remington R, Stamler J, Hawkins CM:** The Hypertension Detection and Follow-up Program design, methods, and baseline characteristics and blood pressure response of the study population. *Progress in Cardiovascular Disease* 29(3) Suppl 1:11-28, 1986.
6. **The HDFP Cooperative Group:** Implications of the Hypertension Detection and Follow-up Program. *Progress in Cardiovascular Disease* 29(3) Suppl 1:3-10, 1986.
7. **Davis BR and Hardy RJ:** A suicide epidemic model. *Social Biology* 33:291-300, 1987.
8. **Davis BR, Langford HG, Blaufox MD, Curb JD, Polk BF, Shulman NB:** The association of systolic blood pressure change and mortality in persons with diastolic hypertension: The HDFP experience. *Circulation* 75(2):340-346, 1987.
9. **Davis BR, Curb JD, Tung B, Hawkins CM, Ehrmann S, Farmer J, Martin M:** Standardized physician preparation of death certificates. *Controlled Clinical Trials* 8:110-120, 1987.
10. **Davis BR, Furberg CD, Williams CB:** Survival analysis of adverse effects data in the Beta-Blocker Heart Attack Trial. *Clinical Pharmacology and Therapeutics* 41:611-615, 1987.
11. Cooper SP, Hardy RJ, Labarthe DR, et al., on behalf of the **HDFP Cooperative Group:** The relationship between degree of blood pressure reduction and mortality among hypertensives in the HDFP. *American Journal of Epidemiology* 127:387-403, 1988.
12. **Davis BR, Friedman LM, Lichstein E:** The prognostic value of the duration of the ambulatory electrocardiogram. *Medical Decision Making* 8:9-18, 1988.
13. **Davis BR, Friedman LM, Lichstein E:** Are 24 hours of ambulatory ECG recording necessary in the post-infarction patient? *American Heart Journal* 115:83-91, 1988.
14. **The HDFP Cooperative Group:** Eight-year follow-up of participants in the Hypertension Detection and Follow-up Program: Persistence of reduction in blood pressure and mortality in a treated hypertensive population. *Journal of the Amer Medical Assoc* 259:2113-2122, 1988.
15. **Davis BR, Curb JD, Borhani NO, Prineas R, Molteni A:** Coffee and serum cholesterol in the Hypertension Detection and Follow-up Program. *American Journal of Epidemiology* 128:124-

- 136, 1988.
16. Daugherty SA on behalf of the **HDFP Cooperative Group**: Mortality findings beyond five years in the Hypertension Detection and Follow-up Program (HDFP). *Journal of Hypertension* 6:S597-S601, 1988.
 17. Stehlin JS, de Ipolyi PD, Greef PJ, McGaff CJ, Jr., **Davis BR**, McNary L: Treatment of cancer of the liver: Experience with infusion and resection in 414 patients. *Annals of Surgery* 208:23-35, 1988. PMID: PMC1493568
 18. **The CRYO-ROP Cooperative Group**: The Multicenter Trial of Cryotherapy for Retinopathy of Prematurity: Preliminary Results. *Archives of Ophthalmology* 106:471-479, 1988.
 19. **The CRYO-ROP Cooperative Group**: The Multicenter Trial of Cryotherapy for Retinopathy of Prematurity: Preliminary Results. *Pediatrics* 81:697-708. 1988.
 20. Stehlin JS, Greef PJ, de Ipolyi PD, Giovanella BC, Klein G, McGaff CJ, Jr., **Davis BR**, Williams LJ, Natelson EA, Anderson RF: Heat as an adjuvant in the treatment of advanced melanoma: An immune stimulant? *Houston Medical Journal* 4:61-82, 1988.
 21. **The Systolic Hypertension in the Elderly Cooperative Research Group**: Rationale and design of a randomized clinical trial on prevention of stroke in isolated systolic hypertension. *Journal of Clinical Epidemiology* 41:1197-1208, 1988.
 22. Shulman NB, Ford CE, Hall WD, et al., on behalf of the **HDFP Cooperative Group**: Prognostic value of serum creatinine and effect of hypertension on renal function. Results From the Hypertension Detection and Follow-up Program. *Hypertension* 13(Suppl 5):I-80 through I-93, 1989.
 23. **Davis BR**, Blaufox MD, Hawkins CM, Langford HG, Oberman A, Swencionis C, Wassertheil-Smoller S, Wylie-Rosett J, Zimbaldi N: Trial of Antihypertensive Interventions and Management: Design, methods, and selected baseline results. *Controlled Clinical Trials* 10:11-30, 1989.
 24. Kulkarni PR, Vernon SW, Jackson GL, Lairson D, **Davis BR**: Stage at diagnosis of breast cancer: A comparative study in a fee-for-service and health maintenance organization practice. *Medical Care* 27:608-622, 1989.
 25. Probstfield JL, Applegate WB, Borhani NO, Curb JD, Cutler JA, **Davis BR**, Furberg CD, Hawkins CM, Lakatos E, Page LB, Perry HM, Jr., Schron E, Smith WM for the SHEP Cooperative Research Group: The Systolic Hypertension in the Elderly Program (SHEP): An intervention trial on isolated systolic hypertension. *Clinical and Experimental Hypertension, Part A: Theory and Practice*, A11(5&6):973-989, 1989.
 26. Langford HG, Rockhold RW, Smoller SW, Oberman A, **Davis BR**, Blaufox MD: Effect of weight loss on thiazide produced erectile problems in men. *Transactions of the American Clinical and Climatological Association* 101:190-194, 1989. PMID: PMC2376483
 27. Oberman A, Smoller SW, Langford HG, Blaufox MD, **Davis BR**, Blaszkowski T, Zimbaldi N, Hawkins CM: Pharmacologic and nutritional treatment of mild hypertension: Changes in

- cardiovascular status. *Annals of Internal Medicine* 112:89-95, 1990.
28. Ramirez G, Grimes RM, Annegers JR, **Davis BR**, Slater CH: Occupational physical activity and other risk factors for preterm birth among U.S. Army primagravidas. *American Journal of Public Health* 80:728-729, 1990.
 29. Hardy RJ and **Davis BR**: The design, analysis, and monitoring of an ophthalmological clinical trial. *American Statistical Association 1989 Proceedings of the Biopharmaceutical Section* 248-253, 1989. (Refereed paper)
 30. **The CRYO-ROP Cooperative Group**: The Multicenter Trial of Cryotherapy for Retinopathy of Prematurity: Three-month outcome. *Archives of Ophthalmology* 108:195-204, 1990.
 31. Dobson V, Quinn GE, Biglan AW, et al., on behalf of the **CRYO-ROP Cooperative Group**: Acuity card assessment of visual function in the Cryotherapy for Retinopathy of Prematurity Trial. *Investigative Ophthalmology & Visual Science* 31:1702-1708, 1990.
 32. Smoller SW, Langford HG, Yamani Y, Blaufox MD, Oberman A, **Davis B**, Narn Y, Wylie-Rosett J, Zimbaldi N: Estimation of protein intake: Comparison of dietary and urinary excretion. *Journal of Cardiovascular Pharmacology* 16 (Suppl 3):28-31, 1990.
 33. **The CRYO-ROP Cooperative Group**: Multicenter Trial of Cryotherapy for Retinopathy of Prematurity: One year outcome--structure and function. *Archives of Ophthalmology* 108:1408-1416, 1990.
 34. **Davis BR** and Hardy RJ: Upper bounds for type I and type II error rates in conditional power calculations. *Communications in Statistics--Theory and Methods* A19(10):3571-3584, 1990.
 35. Langford HG, **Davis BR**, Blaufox MD, Oberman A, Wassertheil-Smoller S, Hawkins M, Zimbaldi N: Effect of drug and diet treatment of mild hypertension on diastolic blood pressure. *Hypertension* 17:210-217, 1991.
 36. Quinn GE, Dobson V, Barr CC, **Davis BR**, Flynn JT, Palmer EA, Robertson J, Trese MT on behalf of the CRYO-ROP Cooperative Group: Visual acuity in infants after vitrectomy for severe retinopathy of prematurity. *Ophthalmology* 98:5-13, 1991.
 37. Phelps DL, Brown DR, Tung B, et al., on behalf of the **CRYO-ROP Cooperative Group**: 28-day survival of 6676 neonates with birth weights of 1250 grams or less. *Pediatrics* 87:7-17, 1991.
 38. Palmer E, Hardy RJ, **Davis BR**, Stein JA, Mowery R, Tung B, Phelps DL, Schaffer DB, Flynn JT, Phillips CL on behalf of the CRYO-ROP Cooperative Group: Operational aspects of early termination in the Multicenter Trial of Cryotherapy for Retinopathy of Prematurity. *Controlled Clinical Trials* 12:277-292, 1991.
 39. Hardy RJ, **Davis BR**, Tung B, Palmer E on behalf of the CRYO-ROP Cooperative Group: Statistical considerations in the early termination of the Multicenter Trial of Cryotherapy for Retinopathy of Prematurity. *Controlled Clinical Trials* 12:293-303, 1991.
 40. Borhani NO, Applegate WB, Cutler JA, **Davis BR**, Furberg CD, Lakatos E, Page L, Perry HM, Smith WM, Probstfield J: The Systolic Hypertension in the Elderly Program (SHEP).

- Part I: Rationale and design. *Hypertension* 17:II-2 - II-15, 1991.
41. Hall WD, **Davis BR**, Frost P, Hoffmeier M, O'Brien JE, Pace S, Page L, Schneider KA, Stamler J: The Systolic Hypertension in the Elderly Program (SHEP). Part 7: Baseline laboratory characteristics. *Hypertension* 17: II-102 - II-122, 1991.
 42. Wittes J, **Davis BR**, Berge K, Cohen JD, Grimm RH, Hawkins CM, Kuller L: The Systolic Hypertension in the Elderly Program (SHEP). Part 10: Analysis. *Hypertension* 17:II-162-167, 1991.
 43. Wassertheil-Smoller S, Blaufox MD, Oberman A, **Davis BR**, Swencionis C, O'Connell-Knerr M, Hawkins CM, Langford HG: Effect of antihypertensives on sexual function and quality of life: The TAIM Study. *Annals of Internal Medicine* 114:613-620, 1991.
 44. Moyé LA, Pfeffer MA, Braunwald E for the **SAVE Investigators**: Rationale design, and baseline characteristics of the Survival and Ventricular Enlargement Trial. *American Journal of Cardiology* 68:70D-79D, 1991.
 45. Wassertheil-Smoller S, **Davis BR**, Oberman A, Blaufox MD, Langford HG, Wylie-Rosett J, Zimbaldi N, Hawkins CM: The TAIM study: Sex-race differences in effects of diet and drugs on cardiovascular risk. *Cardiovascular Risk Factors* 1:427-435, 1991.
 46. Applegate WB, **Davis BR**, Black HR, Smith WM, Miller ST, Burlando AJ on behalf of the SHEP Cooperative Research Group: Prevalence of postural hypotension at baseline in the Systolic Hypertension in the Elderly Program (SHEP). *Journal of the American Geriatric Society* 39:1057-1064, 1991.
 47. **The Systolic Hypertension in the Elderly Program Cooperative Research Group**: Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). *Journal of the American Medical Association* 265:3255-3264, 1991.
 48. Pfeffer MA, Moyé LA, Braunwald E, et al., for the **SAVE Investigators**: Selection bias in the use of thrombolytic therapy in acute myocardial infarction. *Journal of the American Medical Association* 266:528-532, 1991.
 49. Palmer EA, Flynn JT, Hardy RJ, et al., on behalf of the **CRYO-ROP Cooperative Group**: Incidence and early course of retinopathy of prematurity. *Ophthalmology* 98:1628-1640, 1991.
 50. Steingart RM, Packer M, Hamm P, et al., for the **SAVE Investigators**: Sex bias in the management of coronary artery disease. *New England Journal of Medicine* 325:226-30, 1991.
 51. Sacks FM, Pfeffer MA, Moyé LA, et al., for the **CARE Investigators**: Rationale and design of a secondary prevention trial of lowering normal plasma cholesterol levels after acute myocardial infarction: The Cholesterol and Recurrent Events Trial (CARE). *American Journal of Cardiology* 68:1436-1446, 1991.
 52. Langford HG et al. for the **HDFP Cooperative Group**: Effect of thiazide-based therapy on serum alkaline phosphatase. *Journal of Human Hypertension* 5:333-338, 1991.
 53. Loewy J, Kapadia A, Hsi B, **Davis BR**: Statistical methods that distinguish between attributes

- of assessment: Prolongation of life vs quality of life. *Medical Decision Making* 12:83-92, 1992.
54. Wassertheil-Smoller S, Blafox MD, Oberman A, Langford HG, **Davis BR**, Wylie-Rosett J: Adequate weight loss alone and in combination with drug therapy for the treatment of mild hypertension. *Archives of Internal Medicine* 152:131-136, 1992.
 55. Wassertheil-Smoller S, Oberman A, Blafox MD, **Davis B**, Langford H: The Trial of Antihypertensive Interventions and Management (TAIM) Study: Final results with regard to blood pressure, cardiovascular risk, and quality of life. *American Journal of Hypertension* 5:37-44, 1992.
 56. **Davis BR** and Hardy RJ: Repeated confidence and prediction intervals using stochastic curtailment. *Communications in Statistics* 21(2):351-368, 1992.
 57. Quinn G, Dobson V, Repka MX, Reynolds J, Kivlin J, **Davis BR**, Buckley E, Flynn JT, Palmer EA: Development of myopia in infants with birth weight <1251 g. *Ophthalmology* 99:329-340, 1992.
 58. Blafox MD, Lee HB, **Davis BR**, Oberman A, Wassertheil-Smoller S, Langford HG: Renin predicts blood pressure response to nonpharmacologic therapy. *Journal of the American Medical Association* 267:1221-1225, 1992.
 59. Berge KG, Petrovitch H, Vogt T on behalf of the **SHEP Cooperative Research Group**. Isolated systolic hypertension: lowering the risk of stroke in older patients. *Geriatrics*. 47:30-38, 1992.
 60. **The Systolic Hypertension in the Elderly Program Cooperative Research Group**. Isolated systolic hypertension in the elderly. *Focus on Hypertension* 1:5-12, 1992.
 61. **Davis BR**, Oberman A, Blafox MD, Wassertheil-Smoller S, Hawkins CM, Cutler J, Zimbaldi N, Langford HG: Effect of antihypertensive therapy on weight loss. *Hypertension* 19:393-399, 1992.
 62. Lamas, GA et al. for the **Save Investigators**: Do the results of randomized clinical trials of cardiovascular drugs influence clinical practice? *New England Journal of Medicine* 327:241-247, 1992.
 63. Moyé LA, **Davis BR**, Hawkins CM: Analysis of a clinical trial involving a combined mortality and adherence dependent interval censored endpoint. *Statistics in Medicine* 11:1705-1717, 1992.
 64. Pfeffer MA, Braunwald E, Moyé LA, Basta L, Brown EJ, Cuddy TE, **Davis BR**, Geltman EM, Goldman S, Flaker GC, Klein M, Lamas GA, Packer M, Rouleau J, Rouleau JL, Rutherford J, Wertheimer JH, Hawkins C Mon Behalf of the Save Investigators. The effect of captopril on morbidity and mortality in patients with left ventricular dysfunction following myocardial infarction. *New England Journal of Medicine* 327:678-684, 1992.
 65. Gilbert WS, Dobson V, Quinn GE, et al., on behalf of the **CRYO-ROP Cooperative Group**: The correlation of visual function with posterior retinal structure in severe retinopathy of prematurity. *Archives of Ophthalmology* 110:625-631, 1992.

66. Summers GC, Phelps DL, Tung B, et al., on behalf of the **CRYO-ROP Cooperative Group**: Ocular cosmesis in retinopathy of prematurity. *Archives of Ophthalmology* 110:1092-1097, 1992.
67. Coil DR, Giovanella BC, Greef PJ, Stehlin JS, **Davis BR**: An experimental model for the study of thermochemotherapy in vivo. *Anticancer Research* 12:1363-1371, 1992.
68. Wylie-Rosett J, Smoller SW, **Davis BR**, Langford HG, Blaufox MD, Oberman A, Hataway H, Stern J, Jennings S: TAIM: Dietary intervention evaluation. *Journal of American Dietetic Association* 93:408-415, 1993.
69. Schaffer DB, Palmer EA, Plotsky DF et al. on behalf of the **CRYO-ROP Cooperative Group**: Prognostic factors in the natural course of retinopathy of prematurity. *Ophthalmology* 100:230-237, 1993.
70. **The CRYO-ROP Cooperative Group**: Multicenter Trial of CRYO-ROP: 3 1/2 - year outcome - structure and function. *Archives of Ophthalmology* 111:339-344, 1993.
71. Reynolds J, Dobson V, Flynn JT et al., on behalf of the **CRYO-ROP Cooperative Group**: Prediction of visual function in eyes with mild to moderate posterior pole residua of ROP. *Archives of Ophthalmology* 111:1050-1056, 1993.
72. Rouleau JL, Moyer LA, Pfeffer MA, et al. for **the Save Investigators**: A comparison of management patterns after acute myocardial infarction in Canada and the United States. *New England Journal of Medicine* 328:779-84, 1993.
73. **The Systolic Hypertension in the Elderly Program Cooperative Research Group**. Implications of the Systolic Hypertension in the Elderly Program. *Hypertension* 21:335-343, 1993.
74. **Davis BR**, Blaufox MD, Oberman A, Wassertheil-Smoller S, Zimbaldi N, Cutler J, Kirchner K, Langford HG: Reduction in long-term antihypertensive drug requirements: Effects of weight reduction by dietary intervention in overweight persons with mild hypertension. *Archives of Internal Medicine* 153:1773-1782, 1993.
75. Wassertheil-Smoller S, **Davis BR**, Breuer B, Oberman A, Blaufox MD, Chang CJ, Langford HG: Differences in precision of dietary estimates among different population subgroups. *Annals of Epidemiology* 3:619-628, 1993.
76. **Davis BR**, Wittes J, Pressel S, Berge KG, Hawkins CM, Lakatos E, Moyer LA, Probstfield JP: Statistical considerations in monitoring the Systolic Hypertension in the Elderly Program (SHEP). *Controlled Clinical Trials* 14:350-361, 1993.
77. Moyer LA, **Davis BR**, Hawkins CM, Probstfield JP: Conclusions and implications of the Systolic Hypertension in the Elderly Program (SHEP). *Clinical and Experimental Hypertension* 15(6):911-924, 1993.
78. St. John Sutton M, Pfeffer MA, Plappert T et al. for the **SAVE Investigators**: Quantitative two-dimensional echocardiographic measurements are major predictors of adverse cardiovascular events after acute myocardial infarction - The protective effects of captopril.

Circulation 89:68-75, 1994.

79. Moyer LA, Pfeffer MA, Wun CC, **Davis BR** et al. for the SAVE Investigators: Uniformity of captopril benefit in the SAVE study: Subgroup analysis. *European Heart Journal* 15(Suppl B):2-8, 1994.
80. **Davis BR** and Hardy RJ: Monitoring clinical trials: The case for stochastic curtailment. *Journal of Clinical Epidemiology* 47:1033-1042, 1994.
81. **The CRYO-ROP Cooperative Group**: The natural ocular outcome of premature birth and retinopathy: Status at one year. *Archives of Ophthalmology* 112:903,-912, 1994.
82. Rutherford JD, Pfeffer MA, Moyer LA, **Davis BR**, Flaker GC, Kowey PR, Lamas GA, Miller HS, Packer M, Roulaeu JL, Braunwald E on behalf of the SAVE Investigators. Effects of captopril on ischemic events after myocardial infarction. *Circulation* 90:1731-1738, 1994.
83. **Davis BR**, Oberman A, Blaufox MD, Wassertheil-Smoller S, Zimbaldi N, Kirchner K, Wylie-Rosett J, Langford HG: The lack of effectiveness of a low sodium/high potassium diet in reducing antihypertensive medication requirements in overweight persons with mild hypertension. *American Journal of Hypertension* 7:926-932, 1994.
84. Sacks FM, Rouleau JL, Moyer LA, Pfeffer MA, Warnica JW, Arnold JMO, Nash DT, Brown LE, Sestier F, Rutherford J, **Davis BR** Hawkins CM, Braunwald E for the CARE Investigators: Baseline characteristics in the Cholesterol and Recurrent Events (CARE) trial of secondary prevention in patients with average serum cholesterol levels. *American Journal of Cardiology* 75:1116-1119, 1995.
85. Pfeffer MA, Sacks FM, Moyer LA, et al. for the **CARE Investigators**. Cholesterol and recurrent events: A secondary prevention trial for normolipidemic patients. *American Journal of Cardiology* 76:98C-106C, 1995.
86. Simes RJ on behalf of the **PPP and CTT Investigators**. Prospective meta-analysis of cholesterol-lowering studies: The Prospective Pravastatin Pooling Project (PPP) and the Cholesterol Treatment Trialist (CTT) Collaboration. *American Journal of Cardiology* 76:122C-126C, 1995.
87. Wassertheil-Smoller S, **Davis BR**, Blaufox MD, Oberman A, Kirchner K: Gender differences in effects of non-pharmacologic approaches to the treatment of mild hypertension. *American Journal of Human Biology* 7:195-201, 1995.
88. Dobson V, Quinn GE, Saunders RA, Spencer R, **Davis BR**, Risser J, Palmer EA for the Cryotherapy for Retinopathy of Prematurity Cooperative Group: Grating visual acuity in eyes with retinal residua of retinopathy of prematurity (ROP). *Archives of Ophthalmology* 113:1172-1177, 1995.
89. **Davis BR**, Cutler JA, Gordon D, et al. for the ALLHAT Research Group. Rationale and design of the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). *American Journal of Hypertension*. 9:342-360,1996.
90. Blaufox MD, Middleton ML, Bongiovanni J, **Davis BR**: Cost efficacy of the diagnosis and

- therapy of renovascular hypertension. *Journal of Nuclear Medicine* 37:171-177, 1996.
91. Wilt TJ, **Davis BR**, Meryers DG, Rouleau JL, Sacks FM: Prevalence and correlation of diffuse atherosclerosis in individuals with myocardial infarction and normal cholesterol levels: Baseline results from the Cholesterol and Recurrent Events (CARE) Study. *Angiology* 47:533-541, 1996.
 92. Hartley L, Flaker G, Basta L, Menapace F, Golman S, **Davis B**, Hamm P, Lamas G, Moye L, Wun C, Pfeffer M: Physical working capacity in patients with a myocardial infarction and low ejection fraction - captopril effect. *American Journal of Cardiology* 76:857-860, 1995.
 93. Wassertheil-Smoller S., Applegate WB, Berge K, Chang CJ, **Davis BR**, Grimm R, Kostis J, Pressel S, Schron E for the SHEP Cooperative Research Group. Change in depression as a precursor of cardiovascular events. *Archives of Internal Medicine* 156:553-561, 1996
 94. Kostis JA, Berger KG, **Davis BR**, Hawkins CM, Probstfield J. Effect of atenolol and reserpine on selected events in SHEP. *American Journal of Hypertension*. 8:1147-1153, 1995.
 95. **The PPP Project Investigators**. Design, rationale, and baseline characteristics of the Prospective Pravastatin Pooling (PPP) Project. A combined analysis of three large-scale randomized trials - LIPID, CARE, and WOSCOPS. *American Journal of Cardiology* 76:899-905, 1995.
 96. Moye LA, **Davis BR**, Hawkins CM, Sacks F, Pfeffer MA, Cole T, Brown L, Crawford B: Decision rules for predicting lipid values in a cholesterol reduction clinical trial. *Controlled Clinical Trials* 17:536-546, 1996.
 97. **The CRYO-ROP Cooperative Group: Multicenter Trial**: Snellen acuity and structural outcome at 5 1/2 years. *Archives of Ophthalmology* 114:417-424, 1996.
 98. Frost P, **Davis BR**, Burlando AJ et al. Coronary heart disease risk factors in men and women aged 60 and older: Findings from the Systolic Hypertension in the Elderly Program. *Circulation* 94:26-34, 1996.
 99. Quinn GE, Dobson V, Barr CC, **Davis BR**, et al. for the Cryotherapy for Retinopathy of Prematurity Cooperative Group: Visual acuity of eyes after vitrectomy for ROP: Follow-up at 5 1/2 years. *Ophthalmology* 103:595-600, 1996.
 100. Hardy RJ, Palmer EA, Schaffer DB, Phelps DL, **Davis BR**, Cooper CJ for the CRYO-ROP Cooperative Group. Outcome-based management of retinopathy of prematurity. *Journal of American Academy of Pediatric Ophthalmology and Strabismus* 1:46-54, 1997.
 101. Frost P, **Davis BR**, Burlando AJ et al. Serum lipids and the incidence of coronary heart disease: Findings from the Systolic Hypertension in the Elderly Program. *Circulation* 94:2381-2388, 1996.
 102. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, Brown L, Warnica J, Arnold JMO, Wun CC, **Davis BR**, Braunwald E for the Cholesterol and Recurrent Events Trial Investigators. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. *New England Journal of Medicine* 335:1001-9, 1996.

103. Whelton PK, Williamson J, Louis G, Cutler JA, **Davis BR** for the ALLHAT Research Group. Experimental approaches to determining the choice of first therapy for patients with hypertension. *Clinical and Experimental Hypertension* 18:569-579, 1996.
104. Curb JD, Pressel, SL, Culter J, Savage PJ, Applegate WA, Black H, Camel G, **Davis BR**, Frost PH, Gonzalez N, Guthrie G, Oberman A, Rutan G, Stamler J. Low-dose diuretic-based antihypertensive treatment reduces cardiovascular disease risk in older diabetics with isolated systolic hypertension. *JAMA* 276:1886-1892, 1996.
105. Kostis J, **Davis BR**, Cutler JA, et al. Prevention of heart failure by antihypertensive drug treatment in older persons with isolated systolic hypertension *JAMA*.278:212-216, 1997.
106. St. John Sutton M, Pfeffer MA, Moye LA et al. for the **SAVE Investigators**: Cardiovascular death and left ventricular remodeling two years after myocardial infarction.. *Circulation* 96:3294-3299, 1997.
107. Schron EB, Wassertheil-Smoller S, Pressel S et al. on behalf of the **SHEP Investigators**. Clinical trial participant satisfaction: Survey of SHEP enrollees. *J Amer. Geriatric Society* 45:934-938, 1997.
108. Savage PJ, Pressel SL, Curb JD, **Davis BR**, et al. Influence of long-term, low-dose diuretic-based antihypertensive therapy on glucose, lipid, uric acid, and potassium levels in older men and women with isolated systolic hypertension. *Archives of Internal Medicine* 158:741-751, 1998.
109. Hager WD, **Davis BR**, Riba A et al. for the SAVE Investigators. Absence of a deleterious effect of calcium channel blockers in patients with left ventricular dysfunction following myocardial infarction: The SAVE study experience. *American Heart Journal* 135:406-431, 1998.
110. Lewis SJ, Sacks FM, Mitchell JS, et al for the **CARE Investigators**. Effect of pravastatin on cardiovascular events in women after myocardial infarction: a randomized trial, the Cholesterol and Recurrent Events Trial. *Journal of American College of Cardiology* 32:140-146, 1998.
111. Fuller LM, Mirza NQ, Palmer JL, **Davis BR** et al. Hodgkin's Disease: Correlation of clinical characteristics with probabilities for negative lymphangiogram vs. negative laparotomy findings in patients with stage I supradiaphragmatic presentations vs. those in patients with stage II . *International Journal Radiation Oncology Biology Physics* 40(2):377-386, 1998.
112. Sacks FM, Moye LA, **Davis BR**, et al. Relationship between plasma LDL concentration during treatment with pravastatin and recurrent coronary events in the Cholesterol and Recurrent Events Trial. *Circulation* 97:1446-1452, 1998.
113. **World Health Organization-International Society of Hypertension Blood Pressure Lowering Treatment Trialist's Collaboration**. Protocol for prospective collaborative overviews of major randomized trials of blood pressure lowering treatments. *Journal of Hypertension* 16:127-137, 1998.
114. Repka MX, Palmer EA, Summers CG, Dobson V, Tung B, **Davis B**, et al. for the

- Cryotherapy for Retinopathy of Prematurity Cooperative Group. The incidence of ophthalmological interventions in children with birth weights less than 1251 gram: Results through 5 1/2 years. *Ophthalmology* 105:1621-1627, 1998.
115. Wittes J, Lakatos E, Black D, **Davis BR**, et al. Selecting blood pressure entry criteria for the Systolic Hypertension in the Elderly Program (SHEP). *Controlled Clinical Trials* 20:121-132, 1999.
 116. Reynolds JD, Hardy RJ, Kennedy KA et. al. for **the Light-ROP Cooperative Group**. Lack of efficacy of light reduction in preventing retinopathy of prematurity. *NEJM* 338:1572-1576, 1998.
 117. **Davis BR**, Vogt T, Frost PH et al. Risk factors for stroke and stroke type in persons with isolated systolic hypertension. *Stroke* 29:1333-1340, 1998.
 118. Goldberg RB, Mellies M, Sacks FM, Moyé LA, Howard BV, Howard WJ, **Davis BR**, Cole TG, Pfeffer NA, Braunwald E for the CARE Investigators. Cardiovascular events and their reduction with pravastatin in diabetic and glucose intolerant myocardial infarction survivors with average cholesterol levels Observations in the CARE trial. *Circulation* 98:2513-2519, 1998.
 119. Lewis SJ, Moye LA, Sacks FM, Johnstone DE, Timmis G, Mitchell J, Limacher M, Kell S, Glasser SP, Grant J, **Davis BR** et al. for the CARE Investigators Effect of pravastatin on cardiovascular events in older patients after myocardial infarction: a randomized trial, the Cholesterol and Recurrent Events Trial. *Annals of Internal Medicine* 129:681-689, 1998.
 120. Zimmerman J, Fromm R, Meyer D, Boudreaux A, Wun CC, Smalling R, **Davis B** et al. Diagnostic marker cooperative study (DMCS) for the diagnosis of myocardial infarction. *Circulation* 99: 1671-1677, 1999.
 121. Plehn JF, **Davis BR**, Sacks FM et al. for the CARE Investigators. Reduction of stroke incidence following myocardial infarction with pravastatin: The Cholesterol and Recurrent Events (CARE) Study. *Circulation* 99: 216-223, 1999.
 122. Flaker GC, Warnica WJ, Sacks FM Moye LA, **Davis BR**, Rouleau JL, Webel RR, Pfeffer MA, Braunwald E. Pravastatin prevents clinical events in revascularized patients with average cholesterol concentrations. *Journal of American College of Cardiology* 34:106-112, 1999.
 123. Stehlin J, Giovanella B, Natelson E, Depolyi P, Wallace P, Wolk D, Coil D, **Davis BR**, Trojacek A. A study of 9-nitrocamptothecin (RFS-2000) in patients with advanced pancreatic cancer. *Int J Oncol* 14(5):821-931, 1999.
 124. Domanski MJ, **Davis BR**, Pfeffer MA, et al. Isolated systolic hypertension: Prognostic information provided by pulse pressure. *Hypertension* 34:375-380, 1999.
 125. Lai, D, **Davis BR**, Hardy RJ. Fractional Brownian motion and clinical trials. *Journal of Applied Statistics*. 27:103-108, 2000.
 126. **The Light-ROP Cooperative Group**. The design of the multicenter study of light reduction in retinopathy of prematurity. *Journal of Pediatric Ophthalmology and Strabismus* 36:257-

- 263, 1999.
127. Wassertheil-Smoller S, Fann C, Allman RM, Black HR, Camel GH, **Davis B** et al. Relation of low body mass to death and stroke in the Systolic Hypertension in the Elderly Program (SHEP). *Archives of Internal Medicine* 160:494-500, 2000.
 128. **The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group**. Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). *JAMA* 283:1967-1975, 2000.
 129. Amos CI, Gu X, Chen J, **Davis BR**. Least squares estimation of variance components for linkage. *Genetic Epidemiology* 19(Suppl 1):S1-S7, 2000.
 130. Perry HM, **Davis BR**, Price TR, et al. Effect of treating isolated systolic hypertension on the risk of developing various types and subtypes of stroke. The Systolic Hypertension in the Elderly Program. *JAMA* 284:465-471, 2000.
 131. Lai D, Moye LA, **Davis BR**, Brown LE, Sacks FM. Brownian motion and long-term clinical trial recruitment. *J Stat Plan and Infer* 93:239-246, 2001.
 132. **Cryotherapy for Retinopathy of Prematurity Cooperative Group**. Effect of retinal ablative therapy for threshold retinopathy of prematurity: Results of Goldmann perimetry at age 10 years. *Archives of Ophthalmology*. 119:1120-1125, 2001
 133. **Cryotherapy for Retinopathy of Prematurity Cooperative Group**. Multicenter Trial of Cryotherapy for Retinopathy of Prematurity: Ophthalmological outcomes at 10 years. *Archives of Ophthalmology*. 119:1110-1118, 2001
 134. **Cryotherapy for Retinopathy of Prematurity Cooperative Group**. Contrast sensitivity at age 10 years in children who had threshold retinopathy of prematurity. *Archives of Ophthalmology*. 119:1129-1133, 2001
 135. Byington RP, **Davis BR**, Plehn JF et al., for the PPP Investigators. Reduction of Stroke Events with Pravastatin: The Prospective Pravastatin Pooling Project. *Circulation*. 103:387-392, 2001
 136. Pressel SL, **Davis BR**, Wright J et al., Operational aspects of terminating the doxazosin arm of the Antihypertensive and Lipid lowering Treatment to Prevent Heart Attack Trial (ALLHAT) *Cont. Clinical Trials*. 22:29-41, 2001
 137. Bombardier C, Lane L, Reisin A, Shapiro D, Burgos-Vargas R, **Davis BR**, Day R, Ferraz MB, Hawkey CJ, Hochberg MC, Kvien TK, Schnitzer TJ for the VIGOR Study Group. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. *New England Journal of Medicine* 343:1520-1528, 2000 Barzilay J, Jones C, **Davis BR**, et al. Baseline Characteristics of Diabetic Participants in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). *Diabetes Care* 24:654-658, 2001.
 138. **Blood Pressure Lowering Treatment Trialists' Collaboration**. Effects of ACE

- inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomised trials. *Lancet* 355: 1955-1964, 2000.
139. Simes J, Furberg CF, Braunwald E, **Davis BR** et al., for the PPP Investigators. Effect of pravastatin on mortality in patients with and without coronary heart disease across a broad range of cholesterol levels. *European Heart Journal*. 23:207-215, 2002.
 140. Furberg CF, Culter JA, **Davis BR**. Status of alpha-blocker therapy in the treatment of hypertension: Findings of ALLHAT. *Harrison's Online*. Related to Chapter 24.6 www.harrisonsonline.com
 141. Pressel S, **Davis BR**, Louis G et al. Patient recruitment in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). *Controlled Clinical Trials* 22:674-686, 2001.
 142. Wright, J, Cushman W, **Davis BR**, et al.. Clinical center recruitment in the Antihypertensive and Lipid- Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). *Controlled Clinical Trials* 22:659-673, 2001.
 143. Fromm R, Meyer D, Zimmerman J, Boudreaux A, Wun CC, Smalling R, **Davis B**, Habib G, Roberts R. A double-blind, multicentered study comparing the accuracy of diagnostics markers to predict short- and long-term clinical events and their utility in patients presenting with chest pain. *Clin Cardiol*. 24:516-520, 2001.
 144. Pfeffer MA, Keech A, Sacks FM, Cobbe SM, Tonkin A, Byington RP, **Davis BR**, Friedman CP, Braunwald E. Safety and tolerability of pravastatin in long-term clinical trials: Pravastatin Pooling Project. *Circulation* 105(20):2341-2346, 2002.
 145. **Davis BR**, Cutler, JA, Furberg, CD, Wright, JT, Farber, MA, Felicetta, JV, Stokes JD for the ALLHAT Collaborative Research Group Relationship of antihypertensive treatment regimens and blood pressure change with risk of heart failure in hypertensive patients randomized to doxazosin or chlorthalidone: Further analyses from ALLHAT. *Annals of Internal Medicine* 137:313-320, 2002.
 146. Arnett DK, Boerwinkle E, **Davis BR**, Eckfeldt J, Ford CE, Black H. Pharmacogenetic approaches to hypertension therapy: Design and rationale for the Genetics of Hypertension Associated Treatment (GenHAT) Study. *The Pharmacogenomics J*. 2(5):309-17, 2002.
 147. Holmes DR, Goldberg S, Savage M, LaBlanche JM, Serruys PW, Grip L, Zeiher AM, Shapiro LM, Willerson J Fitzgerald P, Ferguson JA, Popma J, King SB, Lincoff AM, Tchong JE, **Davis BR**, Chan R, Poland M, Granett JR Prevention of restenosis with tranilast and its outcomes, the PRESTO trial. *Circulation* 106:1243-1250, 2002.
 148. Laine L, Bombardier C, Hawkey Cj, **Davis B**, Shapiro D, Brett C, Reicin A. Stratifying the risk of NSAID-related upper gastrointestinal clinical events: Results of double-blind outcomes study in patients with rheumatoid arthritis. *Gastroenterology*, 123(4):1006-12, 2002.
 149. Halabi S, Wun CC, **Davis BR**. Analysis of survival data with missing measurements of a time-dependent binary covariate. *Journal of Biopharmaceutical Statistics* 13(2) 253-270,

2003.

150. Piller L, **Davis BR**, Cutler JA, Cushman WC, Wright JT., Williamson J, Leenen F, Randall O, Golden J. Validation of CHF events in ALLHAT participants assigned to doxazosin and chlorthalidone. *Curr Control Trials Cardiovasc Med.* 3:1-10, 2002. PMID: PMC149403
151. Cushman WC, Ford, CE, Cutler JA, Margolis K, **Davis BR**, et al., for the ALLHAT Research Group. Success and Predictors of Blood Pressure Control in Diverse North American Settings: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). *J Clin Hypertens* 4(6):393-404, 2002
152. **The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group.** Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). *JAMA.* 2002 Dec 18;288(23):2981-97.
153. **The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group.** Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT).*JAMA.* 2002 Dec 18;288(23):2998-3007.
154. **ALLHAT Officers and Coordinators for the ALLHAT Cooperative Research Group.** Chlorthalidone versus doxazosin as first-line therapy: Final results from the Antihypertensive and Lipid- Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). *Hypertension* 42:239-246, 2003.
155. Rahman M, Brown CD, Coresh J, **Davis BR** et al for the ALLHAT Collaborative Research Group. The prevalence of reduced glomerular filtration rate (GFR) in older hypertensive patients and its association with cardiovascular disease: A report from the ALLHAT study. *Archives of Internal Medicine.* 164:969-976, 2004.
156. **Blood Pressure Lowering Treatment Trialists' Collaboration.** Lowering regimens on major cardiovascular events: Second cycle of prospectively-designed overviews from the Blood Pressure Lowering Treatment Trialists' Collaboration. *Lancet* 362:1527-35, 2003.
157. Mathew V, Gersh BJ, Williams, BA, Laskey, WK, Willerson JT, Tilbury RT, **Davis BR**, Holmes DR. Outcomes in patients with diabetes mellitus undergoing percutaneous coronary intervention in the current era. *Circulation* 109:476-480, 2004.
158. **Davis BR**, Ford CE, Boerwinkle E, et al. Imputing gene-treatment interactions when the genotype distribution is unknown using case-only and putative placebo analyses—a new method for the Genetics of Hypertension Associated Treatment (GenHAT) Study. *Statistics in Medicine* 23:2413-2427, 2004.
159. Kao J, Tobis J, McClelland RL, Heaton M, **Davis BR**, Currier JW for the PRESTO Investigators Relation of Metformin Treatment to Clinical Events in Diabetic Patients Undergoing Percutaneous Intervention. *Am J Cardiol* 93:1347–1350, 2004.

160. Barzilay JI, **Davis BR**, Bettencourt JB, et al. Cardiovascular outcomes using doxazosin vs chlorthalidone. for the treatment of hypertension in older adults with and without glucose disorders: A report from the ALLHAT study. *J Clin Hypert* 6(3):166-125, 2004.
161. **Davis BR**, Furberg CD, Wright JT, et al. ALLHAT: Setting the Record Straight. *Annals of Internal Medicine*. 141:39-46, 2004.
162. Kenchaiah, S, **Davis BR**, Braunwald E ,et al. Antecedent hypertension and the effect of captopril on the risk of adverse cardiovascular outcomes after acute myocardial infarction: Insights from the Survival and Ventricular Enlargement Trial. *American Heart Journal* 148:356-364, 2004.
163. Best PJ, Berger PB, **Davis BR** et al. Impact of Mild or Moderate Chronic Kidney Disease on the Frequency of Restenosis: Results from the PRESTO Trial. *Journal of American College of Cardiology*. 44:1786-91, 2004.
164. Dickersin K, **Davis BR**, Dixon DO et al. The Society for Clinical Trials support legislation mandating clinical trials registration. *Journal of the Society for Clinical Trials* 5:417-420, 2004.
165. Kostis JB, Wilson AC, Freudenberger RS, Cosgrove NM, Pressel SL, **Davis BR**. Long Term Effect of Diuretic Based Therapy in Subjects with Isolated Systolic Hypertension With and Without Diabetes - Fourteen-Year Follow-up of the Systolic Hypertension in the Elderly Program (SHEP). *American Journal of Cardiology* 95:29-35, 2005.
166. Schabath MB, Grossman HB, Delclos GL, Hernandez LM, Day RS, **Davis BR**, Lerner SP, Spitz MR, Wu X. Dietary Carotenoids and Genetic Instability Modify Bladder Cancer Risk *Journal of Nutrition* 134:3362-3369, 2004.
167. Whelton PK, Barzilay J, Cushman WC, **Davis BR**. Clinical Outcomes in ALLHAT Antihypertensive Trial Participants with Type 2 Diabetes, Impaired Fasting Glucose, and Normoglycemia. *Archives of Internal Medicine* 165:1401-1409, 2005.
168. Wright JT, Dunn K, Cutler JA, **Davis BR** et al. Antihypertensive therapy and race: The Antihypertensive and Lipid-lowering Treatment to Prevent Heart Attack Trial (ALLHAT) experience. *JAMA* 293:1595-1608, 2005.
169. Rahman M, Pressel S, **Davis BR** et al. Renal outcomes in high-risk hypertensive patients treated with an angiotensin-converting enzyme inhibitor or a calcium channel blocker vs a diuretic: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). *Archives of Internal Medicine*. 165;936-946, 2005.
170. **Blood Pressure Lowering Treatment Trialists' Collaboration** . Effects of different blood pressure lowering-regimens on major cardiovascular events in patients with and without diabetes. Results of prospectively-designed overviews of randomised trials. *Archives of Internal Medicine* 16: 1410-1419, 2005.
171. **Eason SL**, Petersen NJ, Suarez-Almazor M, **Davis B**, Collins TC. Diabetes mellitus, smoking, and the risk for asymptomatic peripheral arterial disease: who should we screen? *Journal of the American Board of Family Practice* 18:355-361, 2005.

172. Arnett DK, **Davis BR**, Ford CE, Boerwinkle E, Leindecke-Foster C, Miller M, Black H, Eckfeldt JH. Pharmacogenetic association of the angiotensin converting enzyme insertion-deletion polymorphism on blood pressure and cardiovascular risk in relation to antihypertensive treatment: The GenHAT Study. *Circulation* 111:3374-3383, 2005.
173. **The National, Heart, Lung, Blood Institute Working Group on Future Directions in Hypertension Treatment Trials**. Major clinical trials of hypertension. What should be done next? *Hypertension* 46:1-6, 2005.
174. **Cholesterol Treatment Trialists' (CTT) Collaborators**. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins. *Lancet* 366(9493):1267-1278, 2005.
175. Rahman M, Pressel S, **Davis BR** et al. Cardiovascular outcomes in high-risk hypertensive patients stratified by baseline glomerular filtration rate. *Annals of Internal Medicine*, 144: 172-180, 2006.
176. **Davis BR**, Piller L, Cutler JA. The role of diuretics in the prevention of heart failure. *Circulation* 113:2201-2210, 2006.
177. Leenen F, Nwachuku C, Black HB, **Davis BR**. Comparison of lisinopril and amlodipine in ALLHAT. *Hypertension*. 48:374-384, 2006.
178. Piller LB, Ford CE, **Davis BR**, Nwachuku C, Black H, Oparil S, Gappy S, Retta T, Probstfield J. Incidence and predictors of angioedema in elderly hypertensive patients at high risk for cardiovascular disease: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). *J of Clin Hypert* 8:649-656, 2006.
179. Barzilay JI, **Davis BR**, Cutler JA, Pressel SL, Whelton PK, Basile J, Margolis KL, Ong ST, Sadler LS, Summerson J. Fasting glucose levels and incident diabetes mellitus in older non-diabetic adults randomized to three different classes of antihypertensive treatment: A report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). *Archives of Internal Medicine*. 166:2191-2201, 2006.
180. Bombardier C, Laine L, Burgos-Vargas R, **Davis B**, Day R, Ferraz MB, Hawkey CJ, Hochberg MC, Kvien TK, Schnitzer TJ, Weaver A. Response to expression of concern regarding VIGOR study. *New England Journal of Medicine* 354:1196-1199, 2006.
181. **Davis BR**, Arnett DA, Boerwinkle E, Arnett DA, et al. Antihypertensive therapy, the alpha-adducin polymorphism, and cardiovascular disease in high-risk hypertensive persons: the Genetics of Hypertension-Associated Treatment Study *The Pharmacogenomics Journal* 7:112-122, 2007.
182. Einhorn P, **Davis BR**, Massie B, et al. The validation of the heart failure outcome in ALLHAT. *American Heart Journal*. 153:42-53, 2007.
183. Maitland-van der Zee AK, Boerwinkle E, Arnett DK, **Davis BR** et al. Absence of an interaction between the angiotensin converting enzyme (ACE) insertion-deletion polymorphism and pravastatin on cardiovascular disease in high-risk hypertensives: The GenHAT Study. *American Heart Journal*. 153:54-58, 2007.

184. Barzilay JI, Cutler JA, **Davis BR**. Antihypertensive medications and risk of diabetes mellitus. *Current Opinion in Nephrology and Hypertension*. 16:256-60, 2007.
185. **Blood Pressure Lowering Treatment Trialists' Collaboration**. Blood pressure-dependent and independent effects of agents that inhibit the renin-angiotensin system. *Journal of Hypertension*. 25:951-958, 2007.
186. Lynch AI, Arnett DK, **Davis BR**, Boerwinkle E, Ford CE, Eckfeldt JH, Leidecker-Foster C. Sex-Specific Effects of AGT-6 and ACE I/D on Pulse Pressure After 6 Months on Antihypertensive Treatment: The GenHAT Study. *Annals of Human Genetics*. 71(Pt 6):735-45., 2007.
187. Tonelli M, Pfeffer M, Arnold M, Warnica W, Rouleau J, Moye L, **Davis BR**, Sacks F, Braunwald E. Relation between red blood cell distribution width and cardiovascular event rate in people with coronary disease. *Circulation*. 117(2):163-168, 2008.
188. Black H, **Davis BR**, Barzilay J, Nwachuku C, Baimbridge C, Marginean H, Wright JT, Basile J, Wong ND, Whelton P, Dart RA, Thadani U. Metabolic Syndrome Assigned to Chlorthalidone, Amlodipine, or Lisinopril as Initial Treatment for Hypertension: A Report from the ALLHAT Study. *Diabetes Care*. 31(2):353-60, 2008.
189. Wright JT, Harris-Haywood S, Pressel S, Barzilay J, Baimbridge C, Bareis CJ, Basile JN, Black HR, Dart R, Gupta AK, Hamilton BP, Einhorn PT, Haywood LJ, Jafri S, Louis GT, Whelton PK, Scott CL, Simmons DL, Stanford C, **Davis BR**. Clinical Outcomes by Race in Hypertensive Patients With and Without the Metabolic Syndrome in ALLHAT. *Archives of Internal Medicine*. 168(2):207-17, 2008. PMID: PMC2805022
190. Heidenreich P, **Davis BR**, Cutler JA, Furberg CD, Lairson DR, Shlipak MG, Pressel SL, Nwachuku C, Goldman L. Cost-Effectiveness of Chlorthalidone, Amlodipine, and Lisinopril as First-Step Treatment for Patients with Hypertension: An Analysis of the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). *Journal of General Internal Medicine*. 23:509-16, 2008. PMID: PMC2324242.
191. Garey KW, Lai D, Dao-Tran TK, Gentry LO, Hwang LY, **Davis BR**. Vancomycin Compared to Cefuroxime for Surgical Prophylaxis in Patients Undergoing Cardiac Surgery: An Interrupted Time Series Analysis. *Antimicrobial Agents and Chemotherapy*. 52(2):446-51, 2008. PMID: PMC2224787
192. **Cholesterol Treatment Trialists' (CTT) Collaborators**. Efficacy of statin therapy in people with diabetes: meta-analysis of data from 18,686 diabetic participants in 14 randomised trials of statins. *Lancet* 371(9607):117-25, 2008.
193. Lynch AI, Boerwinkle E, **Davis BR**, Ford CE, Eckfeldt JH, Leidecker-Foster C, Arnett DK. Pharmacogenetic Effect of the *NPPA* Gene on Cardiovascular Disease Outcomes for Hypertensive Patients: The GenHAT Study. *Journal of the American Medical Association*. 299(3):296-307, 2008.
194. Cutler JA and **Davis BR**. Thiazide-type diuretics and beta-adrenergic blockers as first-line drug treatments for hypertension. *Circulation* 117:2691-2704, 2008. PMID: PMC2897820

195. Cushman WC, Ford CE, Einhorn PT, Wright JT Jr, Preston RA, **Davis BR**, Basile JN, Whelton PK, Weiss RJ, Bastien A, Courtney DL, Hamilton BP, Kirchner K, Louis GT, Retta TM, Vidt DG; ALLHAT Collaborative Research Group. Blood pressure control by drug group in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) *J Clin Hypertens*. 10:751-60, 2008. PMID:19090876
196. Rahman M, Baimbridge C, **Davis BR**, Barzilay J, Basile JN, Henriquez JA, Huml, A, Kopyt N, Louis GT, Pressel SL, Rosendorff C, Sastrasinh S. Progression of Kidney Disease in Moderately Hypercholesterolemic, Hypertensive Patients Randomized to Pravastatin vs Usual Care: A report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). *American Journal of Kidney Disease* 52:412-424, 2008. PMID: PMC2897819
197. Patel AB, Kostis JB, Wilson AC, Shea ML, Pressel SL, **Davis BR**. Long-Term Fatal Outcomes in Subjects With Stroke or Transient Ischemic Attack Fourteen-Year Follow-Up of the Systolic Hypertension in the Elderly Program. *Stroke*. 39:1084-1089, 2008.
198. Maitland van der Zee AH, Lynch AI, Boerwinkle E, Arnett DK, **Davis BR**, Leiendecker-Foster C, Ford CE, Eckfeldt JH. Interactions between the SNPs in the homocysteine pathway (MTHFR 677C>T, MTHFR 1298 A>C and CBSins) and the efficacy of HMG-CoA reductase inhibitors in preventing cardiovascular disease in high risk hypertensives: The GenHAT Study. *Pharmacogenetics and Genomics* 18:651-656, 2008. PMID: PMC2729516
199. **Blood Pressure Lowering Treatment Trialists' Collaboration**. Effects of different regimens to lower blood pressure on major cardiovascular events in older and younger people: meta-analysis of randomised trials. *British Medical Journal* 336:1121-1123, 2008.
200. **Davis BR**, Kostis JB, Simpson LM, et al. Heart Failure with Preserved and Reduced Left Ventricular Ejection Fraction in ALLHAT. *Circulation*. 118:2259-2267, 2008. PMID: PMC2775475
201. **Blood Pressure Lowering Treatment Trialists' Collaboration**. Do men and women respond differently to blood pressure lowering treatment? Results of prospectively-designed overviews of randomized trials. *European Heart Journal* 29:2669-2680, 2008.
202. Nwachuku CE, Bastien A, Cutler JA, Grob GM, Margolis K, Roccella EJ, Pressel S, **Davis BR**. Management of High Blood Pressure in Clinical Practice: Perceptible Qualitative Differences in Approaches Utilized by Clinicians. *Journal of Clinical Hypertension*. 10:822-829, 2008.
203. Wright JT, Probstfield JL, Cushman WC, Pressel S, Cutler JA, **Davis BR**, Einhorn PT, Rahman, M, Whelton PK, Ford CE, Haywood LJ, Margolis KL, Oparil S, Black HR, Alderman MH, for the ALLHAT Collaborative Research Group. ALLHAT findings revisited in the context of subsequent analyses, other trials and meta-analyses. *Archives of Internal Medicine* 169: 832-842, 2009. PMID: PMC2803011
204. Maitland-van der Zee AH, Peters P, Lynch AI, Boerwinkle E, Arnett DK, **Davis BR**, Leiendecker-Foster C, Ford CE, Eckfeldt JH. The effect of 9 common polymorphisms in

- coagulation factor genes (F2, F5, F7, F12 and F13) on the effectiveness of statins: The GenHAT Study. *Pharmacogenetics and Pharmacogenomics*. 19:338-44, 2009. PMID: PMC2701506
205. Lynch AI, Boerwinkle E, **Davis BR**, Ford CE, Eckfeldt JH, Leiendecker-Foster C, Arnett DK. Antihypertensive Pharmacogenetic Effect of Fibrinogen-beta Variant -455 G>A on Cardiovascular Disease, End-Stage Renal Disease and Mortality: The GenHAT Study. *Pharmacogenetics and Pharmacogenomics*. 19:415-21, 2009. PMID: PMC2764310
206. Bartholomew LK, Cushman WC, Cutler JA, **Davis BR**, Dawson G, Einhorn PT, Graumlich JF, Piller LB, Pressel S, Roccella EJ, Simpson L, Whelton PK, Williard A. Getting clinical trial results into practice: design, implementation, and process evaluation of the ALLHAT Dissemination Project. *Clinical Trials*, 6:329-43, 2009. PMID: PMC2897824
207. Khoury MJ, McBride C, Schully SC, Ioannidis JPA, Feero WG, Janssens ACJW, Gwinn M, Simons-Morton DG, Bernhardt JM, Cargill M, Chanock SJ, Church GM, Coates RJ, Collins FS, Croyle RT, **Davis BR**, et al. The Scientific Foundation for Personal Genomics: Recommendations from an NIH-CDC Multidisciplinary Workshop. *Genetics in Medicine*, 11:559-67, 2009. PMID: PMC2936269
208. Grimm RH, **Davis BR**, Piller LB, Cutler JA, Margolis KL, Barzilay J, Dart RA, Graumlich JF, Murden RA, Randall OS. Heart failure in ALLHAT: Did blood pressure medication at study entry influence outcome? *Journal of Clinical Hypertension*. 11:466-74, 2009. PMID: PMC2788785
209. Haywood LJ, Ford CE, Crow RS, **Davis BR**, Massie BM, Einhorn PT, Williard A for the ALLHAT Collaborative Research Group. Atrial fibrillation at baseline and during follow-up in ALLHAT. *Journal of the American College of Cardiology* 54:2023-2031, 2009. PMID: Journal, in process.
210. Yeh HW, Chan W, Symanski E, **Davis BR**. Estimating transition probabilities for ignorable intermittent missing data in a discrete-time Markov chain. *Communication in Statistics – Simulation and Computation*. 39:433-448, 2010.
211. Sattar N, Preiss D, Murray HM, Welsh P, Buckley BM, de Craen AJM, Seshasai SRK, McMurray JJ, Freeman DJ, Jukema JW, Macfarlane PW, Packard CJ, Stott DJ, Westendorp RG, Shepherd J, **Davis BR**, Pressel SL, et al. Statins and the risk of incident diabetes: a collaborative meta-analysis of thirteen randomised statin trials involving 91,141 participants. *Lancet* 375:735-742, 2010
212. Stafford RS, Bartholomew LK, Cushman WC, Cutler JA, **Davis BR** et al. for the ALLHAT Collaborative Research Group Impact of the ALLHAT/JNC7 Dissemination Project on Thiazide-type Diuretic Use. *Archives of Internal Medicine* 170:851-858, 2010. PMID: Journal, in process.
213. Einhorn PT, **Davis BR**, Wright JT Jr, Rahman M, Whelton PK, Pressel SL; for the ALLHAT Cooperative Research Group. ALLHAT: still providing correct answers after 7 years. *Current Opinion in Cardiology* 25: 355-365, 2010. PMID: Journal, in process.

214. Irvin MR, Lynch AI, Kabagambe EK, Tiwari HK, Barzilay J, Eckfeldt J, Boerwinkle E, **Davis BR**, Ford C, Arnett D. Pharmacogenetic Association of Hypertension Candidate Genes with Fasting Glucose in the GenHAT Study. *Journal of Hypertension* 28:2076-2083, 2010. PMID: PMC2957368
215. Couch RB, **Davis BR**. Has Oseltamivir Been Shown to Be Effective for Treatment of H5N1 Influenza? *Journal of Infectious Diseases*. 202:1149-1151, 2010.
216. Sherva R, Arnett D, **Davis BR**, Boerwinkle E, Ford CE, Eckfeldt J Pharmacogenetic effect of the stromelysin (MMP3) polymorphism on stroke risk in relation to antihypertensive treatment: The GenHAT Study. *Stroke* 42(2):330-5, 2011.
217. Czernichow F, Zanchetti A, Turnbull F et al. on behalf of the **Blood Pressure Lowering Treatment Trialists' Collaboration**. The effects of blood pressure reduction and of different blood pressure-lowering regimens on major cardiovascular events according to baseline blood pressure: meta-analysis of randomized trials. *Journal of Hypertension*, 29(1):4-16, 2011.
218. **Cholesterol Treatment Trialists'(CTT) Collaboration**. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. *Lancet* 376: 1670–81, 2010.
219. Tanner RM, Lynch AI, Brophy VH, Eckfeldt JH, **Davis BR**, Ford CE, Boerwinkle E, Arnett DK. Pharmacogenetic Associations of MMP9 and MMP12 Variants with Cardiovascular Disease in Patients with Hypertension. *PLoS One* 6(8): e23609, 2010.
220. Piller LB, Baraniuk S, Simpson LM, Cushman WC, Massie BM, Einhorn PT, Oparil S, Ford CE, Graumlich JF, Dart RA, Parish DC, Retta TM, Cuyjet AB, Jafri SZ, Furberg CD, Saklayen MG, Thadani U, Probstfield JL, **Davis BR**. Long-Term Follow-up of Participants with Heart Failure in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). *Circulation* 124:1811-1818, 2011.
221. Cushman WC, **Davis BR**, Pressel SP, et al. ¹Mortality and Morbidity during and after the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). *Journal of Clinical Hypertension* 14(1):20-31, 2012.
222. Kostis JB, Cabrera J, Cheng JQ, Cosgrove NM, Deng Y, Pressel SL, **Davis BR**. Association between chlorthalidone treatment of systolic hypertension and long-term survival. *Journal of the American Medical Association (JAMA)* 306:2588-2593, 2011.
223. Lynch AI, Eckfeldt JH, **Davis BR**, Ford CE, Boerwinkle E, Leidencker-Foster C, Arnett DK. Gene panels to help identify subgroups at high and low risk of CHD among those randomized to antihypertensive treatment: The GenHAT Study. *Pharmacogenetics and Genomics*. 22:355-366, 2012.
224. Barzilay JI, **Davis BR**, Pressel SL, Cutler JA, Einhorn PT, Black HR, Cushman WC, Ford CE, Margolis KL, Mooloo J, Oparil S, Piller LB, Simmons DL, Whelton PK, Wong ND, Wright JT. Long-term Effects of Incident Diabetes Mellitus on Cardiovascular Outcomes in People Treated for Hypertension: The ALLHAT Diabetes Extension Study. *Circulation*:

- Cardiovascular Quality and Outcomes*, 5(2):153-162, 2012.
225. Rahman M, Ford CE, Cutler JA, **Davis BR**, Piller LB, Whelton PK, Wright JT, Barzilay JI, Brown CD, Colon PJ, Fine LJ, Grimm RH, Gupta AK, Baimbridge C, Haywood LJ, Henriquez MA, Ilamaythi E, Oparil S, Preston R, Rayner AV, for the ALLHAT Collaborative Research Group. Long-term renal and cardiovascular outcomes in high-risk hypertensive patients by baseline level of glomerular filtration rate; a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). *Clinical Journal of the American Society of Nephrology* 7:989-1002, 2012.
226. **Cholesterol Treatment Trialists' (CTT) Collaboration**. Lack of effect of lowering LDL cholesterol on cancer risk: Meta-analysis of individual data from 175,000 participants in 27 randomized trials of statin therapy. *PLOS One* 7(1) e29849, 2012.
227. Alderman MH, Piller LB, Ford CE, Probstfield JL, Oparil S, Cushman WC, Einhorn PT, Franklin SS, Papademetriou V, Ong ST, Eckfeldt JH, Furberg CD, Calhoun DA, and **Davis BR**. Clinical significance of incident hypokalemia and hyperkalemia in treated hypertensive patients in ALLHAT. *Hypertension*. 59:926-933, 2012.
228. Zhang X, Lynch AI, **Davis BR**, Ford CE, Boerwinkle E, Eckfeldt JH, Leindecker-Foster C, Arnett DK. Pharmacogenetic Association of NOS3 Variants with Cardiovascular Disease in Patients with Hypertension: The GenHAT Study. *PLOS One*. 2012;7(3):e34217. Epub 2012 Mar 28.
229. **Cholesterol Treatment Trialists' (CTT) Collaborators**. Effects of lowering LDL cholesterol among people at low-risk of vascular disease: meta-analysis of individual data from 27 randomized trials of statin therapy. *Lancet* 380:581-90, 2012.
230. Lynch AI, Irvin MR, Boerwinkle E, **Davis BR**, Vaughan LK, Ford CE, Aissani B, Eckfeldt JH, Arnett DK, Shrestha S. *RYR3* gene polymorphisms and cardiovascular disease outcomes in the context of antihypertensive treatment. *The Pharmacogenomics Journal*. 13(4):330-4, 2013. PMID:22664477
231. Proschan MA, Ford CE, Graumlich JF, Cushman WC, Cutler JA, **Davis BR**, Pavlik VN, Blumenthal SS, Franklin SS, Alderman MH, Furberg CD, Castaldo RS, Preston RA. How much effect of different antihypertensive medications on cardiovascular outcomes is attributable to their effects on blood pressure? *Statistics in Medicine*. 32:884-897, 2013.
232. Drawz PE, Baraniuk S, **Davis BR**, Brown CD, Colon PJ, Cujjet AB, Dart RA, Graumlich JF, Henriquez MA, Moloo J, Sakalayan MG, Simmons DL, Stanford C, Sweeney ME, Wong ND, Rahman M, for the ALLHAT Collaborative Research Group. Cardiovascular risk assessment: addition of CKD and race to the Framingham equation. *American Heart Journal* 164:925-931, 2012.
233. Tilley BC, **Davis BR**. Secondary analyses in cardiovascular clinical trials - statistical and other considerations. *Prog Cardiovasc Dis*. 54(4):329, 2012.
234. Zhang Q, Lai D, **Davis BR**. Stochastically curtailed tests under fractional Brownian motion. *Communications in Statistics - Theory and Methods* 44:1053-1064, 2015.

235. Oparil S, **Davis BR**, Cushman WC, Ford CE, Furberg CD, Habib GB, Haywood J, Margolis K, Probstfield JL, Whelton PK, Wright JT. Mortality and morbidity during and after ALLHAT: Results by gender. *Hypertension* 1:977-986, 2013.
236. Margolis KL, **Davis BR**, Baimbridge C, Ciocon JO, Cuyjet AB, Dart RA, Einhorn PT, Ford CE, Gordon D, Hartney TJ, Haywood LJ, Holtzman J, Mathis DE, Oparil S, Probstfield JL, Simpson LM, Stokes JD, Wiegmann TB, Williamson JD. Long-term follow-up of moderately hypercholesterolemic hypertensive patients following randomization to pravastatin vs. usual care: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT). *Journal of Clinical Hypertension* 15(8):542-54, 2013
237. Rahman M, Baimbridge C, Davis BR, Barzilay J, Basile J, Henriquez M, Pressel S, Huml A, Kopyt N, Louis G, Rosendorff C, Sastrasin S, Stanford C. Pravastatin and cardiovascular outcomes stratified by baseline estimated glomerular filtration rate in the lipid-lowering component of ALLHAT. *Clinical Nephrology* 80(10):235-48, 2013.
238. Luce B, Mullins D, Ishak J, Broglio K, Connor J, Fleurence R, Vanness DJ, Saunders E, **Davis BR**. Do Bayesian Adaptive Trials Offer Advantages for CER? Protocol for the RE-ADAPT Study. *Clinical Trials* 10:807-827, 2013.
239. Phillips W, Piller L, Williamson J, Whittle J, Jafri S, Ford C, Einhorn P, Oparil S, Furberg C, Grimm R, Alderman M, **Davis BR**, Probstfield J. Risk of Hospitalized Gastrointestinal Bleeding in Persons Randomized to Diuretic, ACE-Inhibitor, or Calcium-Channel Blocker in ALLHAT. *Journal of Clinical Hypertension* 15:825–832, 2013.
240. Lynch AI, Irvin MR, **Davis BR**, Ford CE, Eckfeldt JH, Arnett DK. Genetic and adverse health outcome associations with treatment resistant hypertension in GenHAT. *Int J Hypertens* 2013;2013:578578.
241. **Blood Pressure Lowering Treatment Trialists' Collaboration**. The effects of blood pressure-lowering regimens on major cardiovascular events in people with and without chronic kidney disease. *BMJ*. 2013 Oct 3;347:f5680.
242. Kostis JB, Kostis WJ, Cabrera J, Messerli FH, Cheng JQ, Sedjro JE, Cosgrove NM, Swerdel JN, Deng Y, **Davis BR**. Competing Cardiovascular and Non-Cardiovascular Risks and Longevity in the Systolic Hypertension in the Elderly Program. *American Journal of Cardiology*. 113:676-81, 2014.
243. Kostis J, Sejdoro J, Cabrera J, Cosgrove N, Pantazopoulos J, Kostis W, Pressel S, **Davis BR**. Visit-to-Visit Blood Pressure Variability and Cardiovascular Death in the Systolic Hypertension in the Elderly Program. *Journal of Clinical Hypertension*. 16:34-40, 2014
244. Barzilay JL, **Davis BR**, Whelton PK. The Glycemic Effects of Antihypertensive Medications. *Current Hypertension Reports*. 16:410, 2014.
245. Muntner P, Levitan EB, Lynch A, Simpson L, Whittle J, **Davis BR**, Kostis J, Whelton PK, Oparil S. Effect of chlorthalidone, amlodipine and lisinopril on visit-to-visit variability of blood pressure: Results from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). *J Clinical Hypertension* 16:323-30,

2014.

246. Reisin E, Graves J, Yamal JM, Barzilay JI, Pressel SL, Einhorn PT, Dart RA, Retta T, Saklayen MG, Webber JD, **Davis BR**. Blood Pressure Control and Cardiovascular Outcomes in Normal, Overweight, and Obese Hypertensives Treated with Three Different Antihypertensives in ALLHAT. *J of Hypertension*. 32:1503-13, 2014.
247. Shah RV, Abbasi SA, Yamal JM, **Davis BR**, Barzilay J, Einhorn PT, Goldfine A, for the ALLHAT Collaborative Research Group. Impaired fasting glucose and body mass index as determinants of mortality in ALLHAT: Is the obesity paradox real? *J Clinical Hypertension* 16:451-8, 2014.
248. Swerdel JN, Janevic TM, Cabrera J, Cosgrove NM, Sedjro JE, Pressel SL, **Davis BR**, Kostis JB. Rapid decreases in blood pressure from antihypertensive treatment were associated with increased cancer mortality in the systolic hypertension in the elderly program. *Cancer Epidemiol Biomarkers Prev*. 23:1589-97, 2014.
249. Piller LB, Simpson LM, Baraniuk S, Habib GB, Rahman M, Basile JN, Dart RA, Einhorn PT, Ellsworth AJ, Fendley H, Probstfield JL, Whelton PK, **Davis BR**. Characteristics and Long-term Follow-up of Participants with Peripheral Arterial Disease during ALLHAT. *Journal of General Internal Medicine*. 29:1475-83, 2014.
250. Muntner P, **Davis BR**, Cushman WC, Bangalore S, Calhoun DA, Pressel SL, Black HR, Kostis J, Probstfield J, Whelton PK, Rahman M for the ALLHAT Collaborative Research Group. Treatment resistant hypertension and the incidence of cardiovascular disease and end-stage renal disease: Results from ALLHAT. *Hypertension* 64:1012-21, 2014.
251. **Blood Pressure Lowering Treatment Trialists' Collaboration**. Effects of blood pressure lowering on cardiovascular risk according to baseline body mass index: a meta-analysis of randomised trials. *Lancet* Nov 4. pii: S0140-6736(14)61171-5, 2014.
252. **Blood Pressure Lowering Treatment Trialists' Collaboration**. Blood pressure-lowering treatment based on cardiovascular risk: a meta-analysis of individual patient data. *Lancet* 384:591-8, 2014.
253. Sørensen IF, Vazquez AI, Irvin MR, Sørensen P, **Davis BR**, Ford CE, Boerwinkle E, Arnett DK. Pharmacogenetic effects of “candidate gene complexes” on stroke in the GenHAT study. *Pharmacogenetics and Genomics* 24:556-63, 2014.
254. Yamal JM, Oparil A, **Davis BR**, Alderman MH, Calhoun D, Cushman WC, Fendley HF, Franklin SS, Habib GB, Pressel SL, Probstfield JL, Sastrasin S. Stroke outcomes among participants randomized to chlorthalidone, amlodipine or lisinopril in ALLHAT. *Journal of the American Society of Hypertension* 8:808-19, 2014.
255. Anh N Do, Marguerite R Irvin, Amy I Lynch, Steven A Claas, Eric Boerwinkle, **Davis BR**, Charles E Ford, John H Eckfeldt, Hemant K Tiwari, Nita A Limdi, Donna K Arnett The effects of angiotensinogen gene polymorphisms on cardiovascular disease outcomes during antihypertensive treatment in the GenHAT study. *Frontiers in Pharmacogenetics and Pharmacogenomics* 5:210, 2014.

256. Sundstrom J, Arima H, Jackson R, Turnbull F, Rahimi K, Chalmers J, Woodward M, Neal B, on behalf of the **Blood Pressure Lowering Treatment Trialists' Collaboration**. Effects of blood pressure reduction in mild hypertension: systematic review and meta-analysis. *Annals of Internal Medicine* 162:184-91, 2015
257. **Cholesterol Treatment Trialists' (CTT) Collaboration**. Efficacy and safety of LDL-lowering therapy among men and women in secondary and primary prevention: meta-analysis of individual data from 174,000 participants in 27 randomised trials. *Lancet*. 385(9976):1397-405, 2015.
258. Preiss D, Campbell RT, Murray HM, Ford I, Packard CJ, Sattar N, Rahimi K, Colhoun HM, Waters DD, LaRosa JC, Amarenco P, Pedersen TR, Tikkanen MJ, Koren MJ, Poulter NR, Sever PS, Ridker PM, MacFadyen JG, Solomon SD, **Davis BR**, Simpson LM, Nakamura H, Mizuno K, Marfisi RM, Marchioli R, Tognoni G, Athyros VG, Kausik RK, Gotto AM, Clearfield MB, Downs JR, McMurray JJ. The effect of statin therapy on heart failure events: a collaborative meta-analysis of unpublished data from major randomized trials. *European Heart Journal* 36:1536-1546, 2015.
259. Muntner P, Whittle J, Lynch AI, Colantonio LD, Simpson LM, Einhorn PT, Levitan EB, Whelton PK, Cushman WC, Louis GT, **Davis BR**, Oparil S. Visit-to-Visit Variability of Blood Pressure and Coronary Heart Disease, Stroke, Heart Failure, and Mortality: A Cohort Study. *Ann Intern Med*. 163(5):329-38, 2015.
260. **FLAT-SUGAR Trial Investigators**. Design of FLAT-SUGAR: Randomized Trial of Prandial Insulin Versus Prandial GLP-1 Receptor Agonist Together With Basal Insulin and Metformin for High-Risk Type 2 Diabetes. *Diabetes Care*. 38(8):1558-66, 2015.
261. Wanner A, Groft SC, Teagarden JR, Krischer J, **Davis BR**, Coffey CS, Hickam DH, Teckman J, Nelson DR, McCaleb ML, Loomba R, Strange C, Sandhaus RA, Brantly M, Edelman JM, Farrugia. Clinical trial design for alpha-1 antitrypsin deficiency: A model for rare diseases. *Chronic Obstr Pulm Dis* 2:177-190, 2015.
262. Wood JC, Pressel S, Rogers ZR, Odame I, Kwiatkowski JL, Lee MT, Owen WC, Cohen AR, St Pierre T, Heeney MM, Schultz WH, **Davis BR**, Ware RE; TWiTCH Investigators Liver iron concentration measurements by MRI in chronically transfused children with sickle cell anemia: Baseline results from the TWiTCH trial. *Am J Hematol*. 90:806-10, 2015.
263. White IR, Rapsomaniki E, **Emerging Risk Factors Collaboration**. Covariate-adjusted measures of discrimination for survival data. *Biometrical Journal* 57: 592–613, 2015.
264. Monica Teng M, Lin L, Zhao YJ, Khoo AL, **Davis BR**, Yong QW, Yeo TC, Lim BP. Statins for Primary Prevention of Cardiovascular Disease in Elderly Patients: Systematic Review and Meta-analysis. *Drugs & Aging*. ;32:649-661, 2015.
265. Lin LA, Luo S, Chen BE, **Davis BR**. Bayesian analysis of multi-type recurrent events and dependent termination with nonparametric covariate functions. *Statistical Methods in Medical Research* 26(6):2869-2884, 2017.

266. Bis JC, Sitlani C, Irvin R, Avery CL, Smith AV, Sun F, Evans DS, Musani SK, Li X, Trompet S, Krijthe BP, Harris TB, Quibrera PM, Brody JA, Demissie S, **Davis BR**, Wiggins K, Tranah GJ, Lange LA, Sotoodehnia N, Stott DJ, Franco OH, Launer LJ, Stürmer T, Taylor KD, Cupples LA, Eckfeldt JH, Smith NL, Liu Y, Wilson JG, Heckber SR, Buckley BM, Ikram MA, Boerwinkle E, Chen YI, de Craen AJM, Uitterlinden AG, Rotter JI, Ford I, Hofman A, Sattar N, Slagboom PE, Westendorp RGJ, Gudnason V, Vasani RS, Lumley T, Cummings SR, Taylor HA, Post W, Jukema JW, Stricker BH, Whitsel EA, Psaty BM, Arnett D. Drug-gene interactions of antihypertensive medications and risk of incident cardiovascular disease: a pharmacogenomics study from the CHARGE consortium. *PLOS One*. 2015 Oct 30;10(10):e0140496.
267. Alderman MH, **Davis BR**, Piller LB, Ford CE, Baraniuk MS, Pressel SL, Assadi MA, Einhorn PT, Haywood LJ, Ilamathi E, Oparil SO, Retta TM, for the ALLHAT Collaborative Research Group Should Antihypertensive Treatment Recommendations Differ in Patients With and Without Coronary Heart Disease? (From the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial [ALLHAT]). *American Journal of Cardiology*. 117(1):105-15, 2016.
268. Do AN, Lynch AI, Claas SA, Boerwinkle E, **Davis BR**, Ford CE, Eckfeldt JH, Tiwari HK, Arnett DK, Irvin MR. The effects of genes implicated in cardiovascular disease on blood-pressure response to treatment among treatment-naïve hypertensive African Americans in the GenHAT study. *Journal of Human Hypertension*. 2016 Jan 21. doi: 10.1038/jhh.2015.121. [Epub ahead of print]
269. Wood JC, Cohen AR, Pressel SL, Aygun B, Imran H, Luchtman-Jones L, Thompson AA, Fuh B, Schultz WH, **Davis BR**, Ware RE; TWITCH Investigators Organ iron accumulation in chronically transfused children with sickle cell anaemia: baseline results from the TWITCH trial. *Br J Haematol*. 172(1):122-130, 2016.
270. Russell E. Ware, **Barry R. Davis**, William H. Schultz, R. Clark Brown, Banu Aygun, Sharada Sarnaik, Isaac Odame, Beng Fuh, Alex George, William Owen, Lori Luchtman-Jones, Zora R. Rogers, Lee Hilliard, Cynthia Gauger, Connie Piccone, Margaret T. Lee, Janet L. Kwiatkowski, Sherron Jackson, Scott T. Miller, Carla Roberts, Matthew M. Heeney, Theodosia A. Kalfa, Stephen Nelson, Hamayun Imran, Kerri Nottage, Ofelia Alvarez, Melissa Rhodes, Alexis A. Thompson, Jennifer A. Rothman, Kathleen J. Helton, Donna Roberts, Jamie Coleman, Melanie J. Bonner, Abdullah Kutlar, Niren Patel, John Wood, Linda Piller, Peng Wei, Judy Luden, Nicole A. Mortier MHS PA-C, Susan E. Stuber, Naomi L. C. Luban, Alan R. Cohen, Sara Pressel, Robert J. Adams. TCD With Transfusions Changing to Hydroxyurea (TWITCH): a multicentre, randomised controlled trial. *Lancet*. 387(10019):661-70. 2016
271. Luchtman-Jones L, Pressel S, Hilliard L, Brown RC, Smith MG, Thompson AA, Lee MT, Jennifer Rothman, Zora R. Rogers, William Owen, Hamayun Imran, Courtney Thornburg, Janet L. Kwiatkowski, Banu Aygun, Stephen Nelson, Carla Roberts, Cynthia Gauger, Connie Piccone, Theodosia Kalfa, Mathew M. Heeney, Ofelia Alvarez, Beng Fuh, J. Paul Scott, Rachelle Nuss, Kathryn Hassell, **Barry R. Davis**, Russell E. Ware. Effects of

- Hydroxyurea Treatment for Patients with Hemoglobin SC Disease. *American Journal of Hematology* 91(2):238-242, 2016.
272. Jimenez S, Lai D, Gould LK, **Davis BR**. Evaluating the effects of treatment switching with randomization as an instrumental variable in a randomized controlled trial. *Communications in Statistics – Simulation and Computation*. 46:6, 4966-4990, 2017.
273. **Cholesterol Treatment Trialists Collaboration**. Protocol for analyses of adverse event data from randomized controlled trials of statin therapy. *American Heart Journal* 176:63-69, 2016.
274. Kaasenbrood L, Poulter NR, Sever PS, Colhoun HM, Livingstone SJ, Boekholdt SM, Pressel SL, **Davis BR**, van der Graaf Y, Visseren FLJ; on behalf of the CARDS, ALLHAT and ASCOT investigators. Development and validation of a model to predict absolute vascular risk reduction by moderate-intensity statin therapy in individual patients with type 2 diabetes: the ASCOT, ALLHAT and CARDS trials. *Circ Cardiovasc Qual Outcomes*. 9(3):213-21, 2016.
275. Whittle J, Lynch AI, Tanner RM, Simpson LM, **Davis BR**, Rahman M, Whelton PK, Oparil S, Muntner P. Visit-to-Visit Variability of BP and CKD Outcomes: Results from the ALLHAT. *Clin J Am Soc Nephrol*. 11(3):471-80. 2016.
276. Catalá-López F, Macías Saint-Gerons D, González-Bermejo D, Rosano GM, **Davis BR**, Ridao M, Zaragoza A, Montero-Corominas D, Tobías A, de la Fuente-Honrubia C, Tabarés-Seisdedos R, Hutton B. Cardiovascular and Renal Outcomes of Renin-Angiotensin System Blockade in Adult Patients with Diabetes Mellitus: A Systematic Review with Network Meta-Analyses. *PLoS Med*. 13(3):e1001971, 2016.
277. **The Flat-Sugar Trial Investigators**. Glucose Variability in a 26-Week Randomized Comparison of Mealtime Treatment with Rapid-acting Insulin Versus GLP-1 Agonist in Participants with Type 2 Diabetes at High Cardiovascular Risk. *Diabetes Care*. 39(6):973-81, 2016.
279. Kronish IM, Lynch AI, Oparil S, Whittle J, **Davis BR**, Simpson LM, Krousel-Wood M, Cushman WC, Chang TI, Muntner P. The association between antihypertensive medication nonadherence and visit-to-visit variability of blood pressure: findings from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. *Hypertension*. 68(1):39-45, 2016.
280. Dewland TA, Soliman EZ, **Davis BR**, Magnani JW, Yamal JM, Piller LB, Haywood LJ, Alonso A, Albert CM, Marcus GM. Predictors of Conduction System Disease in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). *JAMA Intern Med*. 176:1085-92, 2016.
281. Luce B, Connor J, Broglio K, Mullins D, Ishak J, Saunders E, **Davis BR**. Do Bayesian Adaptive Trials Offer Advantages for Comparative Effectiveness Research? Findings from the RE-ADAPT Study. *Annals of Internal Medicine*. 165:431-438, 2016.
282. Barzilay J, Whelton P, **Davis BR**. Does renin angiotensin system blockade deserve

- preferred status over other anti-hypertensive medications for the treatment of people with diabetes? *Annals of Translational Medicine* 4(10):202-207, 2016.
278. Zhang Q, Lai D, **Davis BR**. Repeated confidence intervals and prediction intervals using stochastic curtailment under fractional Brownian motion. *Communications in Statistics - Theory and Methods* 45:4295-4306, 2016.
283. Lai D, Zhang Q, Yamal J-M, Einhorn PT, **Davis BR**, ALLHAT Collaborative Research Group. Conditional moving linear regression: modeling the recruitment process for ALLHAT. *Communications in Statistics – Theory and Methods* 46: 8943-8951, 2017.
284. Whittle J, Yamal J-M, Williamson JD, Ford CE, Probstfield JL, Beard BL, Marginean H, Hamilton BP, Suhan PS, **Davis BR**. Clinical and demographic correlates and visit adherence in a large randomized controlled trial. *BMC Health Services Research* 16(1):236, 2016.
285. **Cholesterol Treatment Trialists’ (CTT) Collaboration**. Impact of renal function on the effects of LDL cholesterol lowering with statin-based regimens: a meta-analysis of individual participant data from 28 randomized trials. *The Lancet Diabetes & Endocrinology*. 4(10):829-39, 2016.
286. Whelton PK, Einhorn PT, Muntner P, Appel LJ, Cushman WC, Diez-Roux AV, Ferdinand KC, Rahman M, Taylor HA, Ard J, Arnett DK, Carter BL, **Davis BR**, Freedman BI, Cooper LA, Cooper R, Desvigne-Nickens P, Gavini N, Go AS, Hyman DJ, Kimmel PL, Margolis KL, Miller III ER, Mills KT, Mensah GA, Navar AM, Ogedegbe G, Rakotz MK, Thomas G, Tobin JN, Wright JT, Yoon SS, Cutler JA. Research Needs to Improve Hypertension Treatment and Control in African Americans. *Hypertension* 68:1066-1072, 2016.
287. Puttnam R, **Davis BR**, Pressel SL, Whelton PK, Cushman WC, Louis GT, Margolis KL, Oparil S, Williamson J, Ghosh A, Einhorn PT, Barzilay JI, ALLHAT Collaborative Research Group. Hip and Pelvic Fracture Risk in Older Adults Randomized to Three Different Anti-hypertensive Medications. *JAMA Internal Medicine*. 77:67-76, 2017.
288. Chen DP, **Davis BR**, Simpson LM, Cushman WC, Cutler JA, Dobre M, Ford CE, Louis GT, Muntner P, Oparil S, Piller LB, Pressel SL, Sarnak MJ, Whelton PK, Wright JT, Rahman M, ALLHAT Collaborative Research Group. Association between Chronic Kidney Disease and Cancer Mortality: A report from ALLHAT. *Clinical Nephrology*. 87:11-20, 2017.
289. Schaefer BA, Flanagan JM, Alvarez OA, Nelson SC, Aygun B, Gee BE, Nottage KA, George A, Roberts CW, Piccone CM, Miller ST, Howard TA, **Davis BR**, Ware RE. Genetic Modifiers of Disease Severity in Children with Sickle Cell Anemia. *PLOS One*. Oct 6;11(10):e0164364, 2016.
290. Bangalore S, **Davis BR**, Cushman WC, Pressel SL, Muntner PM, Calhoun DA, Kostis JB, Whelton PK, Probstfield JL, Rahman M, Black HR, ALLHAT Collaborative Research Group. Treatment Resistant Hypertension and Outcomes based on Randomized Treatment Group in ALLHAT. *American Journal of Medicine*. 130(4):439-448, 2017.

291. Ernst ME, **Davis BR**, Soliman EZ, Prineas RJ, Okin PM, Ghosh A, Cushman WC, Einhorn PT, Oparil S, Grimm, RH Jr, ALLHAT Collaborative Research Group. Electrocardiographic Measures of Left Ventricular Hypertrophy in the Antihypertensive and Lipid-Lowering to Prevent Heart Attack Trial. *Journal of the American Society of Hypertension*. 10(12):930-938, 2016.
292. Paige E, Barrett J, Pennells L, Sweeting M, Willeit P, Di Angelantonio E, Gudnason V, Nordestgaard BG, Psaty BM, Goldbourt U, Best LG, Assmann G, Salonen JT, Nietert PJ, Verschuren WM, Brunner EJ, Kronmal RA, Salomaa V, Bakker SJ, Dagenais GR, Sato S, Jansson JH, Willeit J, Onat A, de la Cámara AG, Rousset R, Völzke H, Dankner R, Tipping RW, Meade TW, Donfrancesco C, Kuller LH, Peters A, Gallacher J, Kromhout D, Iso H, Knuiman M, Casiglia E, Kavousi M, Palmieri L, Sundström J, **Davis BR**, Njølstad I, Couper D, Danesh J, Thompson SG, Wood A. Repeated measurements of blood pressure and cholesterol improves cardiovascular disease risk prediction: an individual-participant-data meta-analysis. *American Journal of Epidemiology*. 186:899-907, 2017.
293. Haywood LJ, **Davis BR**, Piller LB, Cushman WC, Cutler JA, Ford CE, Simpson LM, Ghosh A, Soliman EZ, Jackson TW, ALLHAT Collaborative Research Group. Influence of Prevalent and Incident Atrial Fibrillation on Post-Trial Major Events in ALLHAT. *Journal of the National Medical Association*. 109:172-18, 2017.
294. Han BH, Sutin D, Williamson JD, **Davis BR**, Piller L, Pervin H, Pressel S, Blaum C. Outcomes among older adults randomized to statin treatment or usual care for primary prevention: results from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT) - A Randomized Clinical Trial. *JAMA Internal Medicine*. 177(7):955-965, 2017.
295. Dhruva SS, Huang C, Spatz ES, Coppi AC, Warner F, Li S-X, Lin H, Xu X, Furberg CD, **Davis BR**, Pressel SL, Coifman RR, Krumholz HM. SM Heterogeneity in Early Responses in ALLHAT. *Hypertension* 70(1):94-102, 2017.
296. Haywood LJ, **Davis BR**, Piller LB, Simpson LM, Ghosh A, Einhorn PE, Ford CE, Probstfield JL, Soliman EZ, Jackson TW, ALLHAT Collaborative Research Group. Risk Factors Influencing Outcomes of Atrial Fibrillation in ALLHAT. *Journal of the National Medical Association*. 110:343-351, 2018.
297. Barzilay JI, **Davis BR**, Pressel SL, Whelton P, Ghosh A, Puttnam R, Margolis K The Impact of Antihypertensive Medications on Bone Mineral Density and Fracture Risk. *Current Cardiology Reports*. 2017 19:76.
298. Bang CN, Soliman EZ, Simpson LM, **Davis BR**, Devereux RB, Okin PM; and for the ALLHAT Collaborative Research Group. Electrocardiographic Left Ventricular Hypertrophy Predicts Cardiovascular Morbidity and Mortality in Hypertensive Patients: The ALLHAT Study. *Am J Hypertens* 30:914-922.
299. Lin LA, Luo S, **Davis BR**. Bayesian regression model for recurrent event data with event-varying covariate effects and event effect. *Journal of Applied Statistics*. 45:1260-1276, 2018.

300. Alvarez O, Nottage K Simpson LM, Wood J, **Davis BR**, Fuh B, Sarnaik S Aygun B, Helton K, Ware RE. Kidney function of transfused children with sickle cell anemia: baseline data from the TWiTCH study with comparison to non-transfused cohorts. *American Journal of Hematology*. 92:E637-E639, 2017.
301. Tereshchenko LG, Soliman EZ, **Davis BR**, Oparil S. Risk stratification of sudden cardiac death in hypertension. *Journal of Electrocardiology*. 50:798-801, 2017.
302. Shams T, Alexander Auchus A, Suzanne Oparil S, Clinton Wright C, Wright J, Furlan A, Sila C, **Davis BR**, Pressel S, Yamal JM, Einhorn P, Lerner A. Baseline Quality of Life and Risk of Stroke in the ALLHAT study. *Stroke*. 48:3078-3085, 2017.
303. Dewland TA, Soliman EZ, Yamal JM, **Davis BR**, Alonso A, Alpert CM, Simpson LM, Haywood LJ, Marcus GM. Pharmacologic Prevention of Incident Atrial Fibrillation: Long-Term Results from the ALLHAT (Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial). *Circ Arrhythm Electrophysiol* 2017 Dec;10(12). pii: e005463. doi: 10.1161/CIRCEP.117.005463.
304. Angelini P, Cheong BY, Lenge De Rosen VV, Lopez JA, Uribe C, Masso AH, Ali SW, **Davis BR**, Muthupillai R, Willerson JT. Magnetic resonance imaging-based screening study in a general population of 5,243 adolescents. *JACC*. 71:579–580, 2018.
305. Barzilay JI, **Davis BR**, Pressel SL, Ghosh A, Rahman M, Einhorn PT, Cushman WC, Whelton PK. The effects of eGFR change on CVD, renal, and mortality outcomes in a hypertensive cohort treated with three different antihypertensive medications. *American Journal of Hypertension*. 31:609-614, 2018
306. Karmali KN, Lloyd-Jones DM, van der Leeuw J, Goff DC Jr., Yusuf S, Zanchetti A, Glasziou P, Jackson R, Woodward M, Rodgers A, Neal BC, Berge E, Teo K, **Davis BR**, Chalmers J, Pepine C, Rahimi K, Sundström J;Blood Pressure Lowering Treatment Trialists' Collaboration. Blood pressure-lowering treatment strategies based on cardiovascular risk versus blood pressure: A meta-analysis of individual participant data. *PLOS Medicine*. 2018 Mar 20;15(3):e1002538.
307. Barzilay JI, **Davis BR**, Ghosh A, Pressel SL, Rahman M, Einhorn PT, Cushman WC, Whelton PK, Wright JT, ALLHAT Collaborative Research Group. Rapid eGFR change as a determinant of cardiovascular and renal disease outcomes and of mortality in hypertensive adults with and without type 2 diabetes. *Journal of Diabetes and its Complications*. 32:830-832, 2018.
308. **Davis B**, Kerr D, Maguire M, Sanders C, Snapinn S, Wittes J. University of Pennsylvania 10th annual conference on statistical issues in clinical trials: Current issues regarding data and safety monitoring committees in clinical trials (morning panel session). *Clinical Trials* 15:335-351, 2018.
309. Angelini P, Cheong BY, Lenge De Rosen VV, Lopez JA, Uribe C, Masso AH, Ali SW, **Davis BR**, Muthupillai R, Willerson JT. High-Risk Cardiovascular Conditions in Sports-Related Sudden Death: Prevalence in 5,169 Schoolchildren Screened via Cardiac Magnetic Resonance. *Texas Heart Institute Journal* 45:205-213, 2018.

310. Berkelmans GFN, Gudbjörnsdottir S, Visseren FLJ, Wild SH, Franzen S, Chalmers J, Davis BR, Poulter NR, Spijkerman AM, Woodward M, Pressel SL, Gupta AK, van der Schouw YT, Svensson AM, van der Graaf Y, Read SH, Eliasson B, Dorresteijn JAN. Prediction of individual life-years gained without cardiovascular events from lipid, blood pressure, glucose, and aspirin treatment based on data of more than 500,000 patients with type 2 diabetes mellitus. *European Heart Journal*. 40:2899-2906, 2019.
311. Cholesterol Treatment Trialists' Collaboration. Efficacy and safety of statin therapy in older people: a meta-analysis of individual participant data from 28 randomised controlled trials. *Lancet*. 393(10170):407-415, 2019.
312. Pennells L, Kaptoge S, Wood A, ..., Davis BR, ..., Thompson SG, Danesh J, Di Angelantonio E on behalf of The Emerging Risk Factors Collaboration. Equalization of four cardiovascular risk algorithms after systematic recalibration: individual-participant meta-analysis of 86 prospective studies. *European Heart Journal* 40:621-631, 2019.
313. Salam A, Atkins E, Sundström J, Hirakawa Y, Ettehad D, Emdin C, Neal B, Woodward M, Chalmers J, Berge E, Yusuf S, Rahimi K, Rodgers A, Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of blood pressure lowering on cardiovascular events, in the context of regression to the mean: a systematic review of randomized trials. *J Hypertens*. 37:16-23, 2019.
314. Barzilay JI, Lai D, Davis BR, Pressel S, Pervin H, Arnett D. The interaction of a diabetes gene risk score with three different antihypertensive medications for incident glucose level elevation. *American Journal of Hypertension*. 32:343-349, 2019.
315. Bowling CB, Davis BR, Luciano A, Simpson LM, Sloane R, Pieper C, Einhorn PT, Oparil S, Muntner P. Sustained blood pressure control and coronary heart disease, stroke, heart failure and mortality: An observational analysis of ALLHAT. *Journal of Clinical Hypertension*. 21:451-459, 2019.
316. Kostis W, Sargsyan D, Mekkaoui C, Moreyra A, Cabrera J, Cosgrove N, Sedjro J, Kostis J, Cushman W, Pantazopoulos J, Pressel S, Davis B. Association of orthostatic hypertension with mortality in the Systolic Hypertension in the Elderly Program. *J Human Hypertension*. 33:735-740, 2019.
317. Johnson K, Oparil S, **Davis BR**, Tereshchenko LG. Prevention of heart failure in hypertension-disentangling the role of evolving left ventricular hypertrophy and blood pressure lowering: The ALLHAT Study. *J Am Heart Assoc*. 2019 Apr 16;8(8):e011961.
318. Rahimi K, Canoy D, Nazarzadeh M, Salimi-Khorshidi G, Woodward M, Teo K, **Davis BR**, Chalmers J, Pepine CJ on behalf of the Blood Pressure Lowering Treatment Trialists' Collaboration. Investigating the stratified efficacy and safety of pharmacological blood pressure-lowering: an overall protocol for individual patient-level data meta-analyses of over 300 000 randomised participants in the new phase of the Blood Pressure Lowering Treatment Trialists' Collaboration (BPLTTC). *BMJ Open* 2019;9:e028698. doi:10.1136/bmjopen-2018-028698
319. Sinha AK, Moye L, Piller LB, Yamal JM, Barcenas CH, Lin J, **Davis BR**. Adaptive group-

- sequential design with population enrichment in phase 3 randomized controlled trials with two binary co-primary endpoints. *Statistics in Medicine*. 38:3895-3996, 2019.
320. Shahu A, Herrin J, Dhruva SS, Desai NR, **Davis BR**, Krumholz HM, Spatz ES. Disparities in socioeconomic context and association with blood pressure control and cardiovascular outcomes in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). *J Am Heart Assoc*. 2019 Aug 6;8(15):e012277.
321. Juraschek SP, Simpson LM, **Davis BR**, Beach JL, Ishak A, Mukamal KJ. Effects of antihypertensive class on falls, syncope, and orthostatic hypotension in older adults: The ALLHAT Trial. *Hypertension* 1033-1040, 2019.
322. Ho CLB, Breslin M, Chowdhury EK, Doust J, Reid CM, **Davis BR**, Simpson LM, Nelson MR. Lack of a significant legacy effect of baseline blood pressure 'treatment naivety' on all-cause and cardiovascular mortality in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. *J Hypertens*. 38:519-526, 2020.
323. Ho CLB, Sanders S, Breslin M, Doust J, Reid CM, **Davis BR**, Simpson LM, Brouwers FP, Nelson MR. Legacy effect of delayed blood pressure lowering drug treatment in middle-aged adults with mildly elevated blood pressure: systematic review and meta-analysis. *J Hum Hypertens*. 34:261-270, 2020.
324. Juraschek SP, Simpson LM, **Davis BR**, Shmerling RH, Beach JL, Ishak A, Mukamal KJ. The effects of antihypertensive class on gout in older adults: Secondary analysis of the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. *J Hypertens* 38:954-960, 2020.
325. Bowling CB, Sloane R, Pieper C, Luciano A, **Davis BR**, Simpson LM, Einhorn PT, S Oparil S, Muntner P. Association of sustained blood pressure control with multimorbidity progression among older adults. *Journal of the American Geriatrics Society* 2020 [Online ahead of print].
326. Juraschek SP, Hu JR, Cluett JL, Ishak A, Mita C, Lipsitz LA, Appel LJ, Beckett NS, Ruth L, Coleman RL, Cushman WC, Davis BR, Grandits G, Holman RR, Miller ER, Peters R, Staessen JA, Taylor AA, Thijs L, Wright JT, Mukamal KJ. Effects of Intensive Blood Pressure Treatment on Orthostatic Hypotension : A Systematic Review and Individual Participant-based Meta-analysis *Ann Intern Med* 2020 In Press.
327. Khayyat-Kholghi M, Oparil S, **Davis BR**, Tereshchenko LG. Worsening kidney function is the major mechanism of heart failure in hypertension: the ALLHAT study. *JACC: Heart Failure*. 2020 In Press.
328. Bolli R, Perin EC, Willerson JT, Yang PC, Traverse JH, Henry TD, Pepine CJ, Mitrani RD, Hare JM, Murphy, MP, March KI, Ikram S, Lee DP, O'Brien C, Durand JB, Miller K, Lima JA, Ostovaneh MR, Ambale-Venkatesh B, Gee AP, Richman S, Taylor DA, Sayre SL, Bettencourt J, Vojvodic R, Cohen ML, Simpson LM, Lai D, Aguilar D, Loghin C, Moyé L, Ebert RF, **Davis BR**, Simari RD for the Cardiovascular Cell Therapy Research Network (CCTRN). Allogeneic Mesenchymal Cell Therapy Anthracycline-Induced Cardiomyopathy Heart Failure Patients The CCTRN SENECA Trial. *JACC: Oncology*. 2020

In Press.

BOOK CHAPTERS

1. Probstfield JL, Applegate WB, Curb JD, Borhani NO, Hawkins CM, Cutler JA, **Davis BR**, Furberg CD, Lakatos E, Page LB, Perry HM, Jr., Smith WM for the SHEP Cooperative Research Group: The Systolic Hypertension in the Elderly Program (SHEP): Rationale, design, recruitment, and baseline data. In Omae T and Atanchetti A, editors, *How Should Elderly Hypertensive Patients Be Treated?* Tokyo, Springer-Verlag, pp 135- 142, 1989.
2. Perry HM, Berge KG, Blaufox MD, **Davis BR**, Grimm RH, McDonald R, Pressel S, Schron E, Smith WM, Vogt TM: The systolic hypertension in the elderly program. In Leonetti G and Cuspidi C, eds., *Hypertension in the Elderly*, Kluwer Academic Publishers, pp.123-137, 1994.
3. **Davis BR**, Ford CE. The Hypertension and Detection Follow-Up Program. *Clinical Trials in Hypertension* edited by Henry Black. Marcel Dekker, New York, 2001.
4. Cutler JA, Gordon DJ, **Davis BR**, Wright J., Furberg CD. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. *Clinical Trials in Hypertension* ed Henry Black. Marcel Dekker, NY, 2001.
5. Probstfield JP, **Davis BR** The Systolic Hypertension in the Elderly Program. *Clinical Trials in Hypertension* edited by Henry Black. Marcel Dekker, New York, 2001.
6. Sacks FM, Pfeffer MA, Moye LA, Hawkins CM, **Davis BR**, Rouleau JL, Cole, TG, Braunwald E. The Cholesterol and Recurrent Events Trial. *Cholesterol-Lowering Therapy: Evaluation of Clinical Trial Evidence* Edited by: Scott M. Grundy,. Marcel Dekker, New York, 1999.
7. **Davis BR** and Cutler JA. Data Monitoring in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. *Data Monitoring in Clinical Trials: A Case Studies Approach* DeMets, David L.; Furberg, Curt D.; Friedman, Lawrence (Eds.) Springer, 2005.
8. **Davis BR**, Baraniuk S. Definitive Phase III and Phase IV Clinical Trials. *Handbook of Statistics 27 - Epidemiology and Medical Statistics – Rao CR, Miller JP, Rao DC (Eds.)* Elsevier, Amsterdam, 2007.
9. Barzilay JL, Whelton PK, **Davis BR**. The Glycemic Consequences of Antihypertensive Medications. *Pathophysiology and Pharmacotherapy of Cardiovascular Disease*. Editors: Jagadeesh, Gowraganahalli, Balakumar, Pitchai, Maung-U, Khin (Eds.) Springer, New York, 2015.

PUBLISHED REPORTS:

1. **B. Davis** and S. Geman. The application of neurobiological and statistical concepts to machine intelligence. *Reports on Pattern Analysis* No. 129, Division of Applied Mathematics, Brown University, 1983.
2. Pfeffer MA, Braunwald E, Moyé LA et al. for the Save Investigators: The effect of captopril

- on morbidity and mortality in patients with dysfunction of the left ventricle after myocardial infarction. Results on survival and hypertrophic studies. *Kardiologia* 33(12):14-23, 1993.
3. Peterson LE, Schull WJ, **Davis BR**, Buffler PA: *Information Bias and Lifetime Mortality Risks of Radiation Induced Cancer*. U.S. Nuclear Regulatory Commission, NUREG/GR-0011, 1994.
 4. **Davis BR**, Blafox MD, Oberman A, Wassertheil-Smoller S, Zimbaldi N, Cutler JA, Kirchner K, Langford HG. Reduction in long-term antihypertensive medications. *Cardiology Board Review*, October, 1994.
 5. Wassertheil-Smoller S, Blafox MD, **Davis BR**, Kirchner K, Langford HG, Oberman A: The trial of antihypertensive interventions and management (TAIM). *Nieren- und Hochdruckkrankheiten, Jahrgang 23*, 1. Supplement, S22-S27, 1994.
 6. Fortmann SP, Bond NG, Byington RP, **Davis BR**, Eaker E, Folsom AR, Haskell WL, Probstfield JL: Annotated Bibliography of Epidemiological Methods of Cardiovascular Research. Committee on Criteria/Methods of the Council of Epidemiology, American Heart Association, 1989.
 7. Wassertheil-Smoller S, Blafox MD, Oberman A, **Davis BR**, Swencionis C, O'Connell Knerr, M, Hawkins CM, Langford HG: The TAIM Study: Antihypertensive therapy's effect on the quality of life. *Cardiology Board Review* 9:65-72, 1992.
 8. Wassertheil-Smoller S and **Davis BR**: Quality of life and antihypertensive therapy. *Primary Cardiology* 18(11):54-60, 1992.
 9. Probstfield JL, Borhani NO, Cutler JA, **Davis B**, Egan D, Pressel S, Yusuf S: Adherence to lifestyle changes and pharmacotherapy among elderly individuals in clinical trials. Proceedings *Inclusion of Elderly Individuals in Clinical Trials: Cardiovascular Disease/Therapy as a Model*. Marion Merrel Dow, Inc. Kansas City, MO. 155-166. 1993.

LETTERS:

1. Oberman A for the **TAIM Research Group**: Mild hypertension and cardiovascular risks. Response to Letter to the Editor *Annals of Internal Medicine* 112:879, 1990.
2. Cooper SP, Ford CE, Hardy RJ, **Davis BR**, Hawkins CM, Labarthe DL: The "J-shaped" relationship in hypertension treatment. Letter to the Editor. *The American Journal of Hypertension* 3:733-734, 1990.
3. Wassertheil-Smoller S. for the **TAIM Research Group**: Clinical trials and the elderly. Response to Letter to the Editor *Annals of Internal Medicine* 115:497, 1991.
4. Stamler J, Berge KG, **Davis BR**, Hadley E, Pressel S, Probstfield J, for the Systolic Hypertension in the Elderly Program Research Group: Prevention of stroke in older persons with isolated systolic hypertension (letter to the editor, in reply) *JAMA* 266:2829-2830, 1991.
5. Smith WM, Stamler J, Pressel SL, Berge KG, Hawkins CM, **Davis BR**, Schron E, Cutler JA: Inverse association between baseline pressure and benefit from treatment in isolated systolic hypertension. Response to Letter to the Editor. *Hypertension* 23: 269-270, 1994.

6. Proschan M, **Davis B**, Cutler J et al. for the ALLHAT Research Group. ALLHAT and calcium channel blockers. Letter to the Editor. *American Journal of Hypertension* 10:142-143, 1996.
7. Quinn GE, Dobson V, Barr CC, **Davis BR**, Palmer EA, Robertson J, Summers CG, Trese MT, Tung B, on behalf of the Cryotherapy for Retinopathy of Prematurity Cooperative Group. Reply to Letter to the Editor: Lambert SR, Capone A, Jr. Visual Acuity of eyes after vitrectomy for ROP: Follow-up at 5 1/2 years. *Ophthalmology* 103(9): 1331-1332, 1997.
8. Sacks FM, Pfeffer MA, Braunwald E, Goldberg RB, Mellies MJ, Moye LA, **Davis BR**, Howard BV, Howard WJ, Cole TG. Baseline cholesterol level and magnitude of coronary event reduction in diabetic patients with myocardial infarction. Response. *Circulation* 100:154e, 1999.
9. Wright JT, **Davis BR**, Cutler JA. Long-term Cardiovascular Consequences of Diuretics vs Calcium Channel Blockers vs Angiotensin-Converting Enzyme Inhibitors—Reply. *JAMA*. 289:2069-2070, 2003.
10. **Davis BR**, Wright JT, Culter JA. The Australian National Blood Pressure Study II. *NEJM*. 349:90, 2003.
11. **Davis BR**, Furberg CD, Wright JT, et al. Angiotensin-converting enzyme inhibitors and diuretics: Optimal combination therapy - Response. *Annals of Internal Medicine* 141 (11): 893-893, 2004.
12. Rahman M, Pressel SL, **Davis BR**. Omission of drug dose information - Reply. *Archives of Internal Medicine* 166 (3): 368-369 , 2006.
13. Rahman M, Nwachuku C, Whelton P, Probstfield J, **Davis BR**. Re: Hawkins RG, Houston MC Is population-wide diuretic use directly associated with the incidence of end-stage renal disease in the United States? A hypothesis. *Am J Hypertens*. 19:656-657, 2006.
14. **Davis BR**, Piller LB, Dunn K. Response to letter regarding article, "Role of diuretics in the prevention of heart failure: The antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT)" *Circulation* 115:E19, 2007.
15. Barzilay JI, Cutler JA, **Davis BR**, et al. What if chlorthalidone-associated hyperglycemia develops? Reply *Archives of Internal Medicine*, 167:1434-1435, 2007.
16. Cutler JA, **Davis BR**. Risk/benefit assessment of beta-blockers and diuretics precludes their use for first-line therapy in hypertension. *Circulation* 117: 2715, 2008.
17. Kostis JB, Pressel SL, **Davis BR**. Response to Letter by Bath et al. *Stroke*. 2008;29:e146.
18. **Davis BR**, Whelton PK, for the ALLHAT Collaborative Research Group. Response to ACCOMPLISH trial. *New England Journal of Medicine*. 360:1148-9, 2009.
19. **Davis BR**, Kostis JB, Simpson LM, et al. Response to Letter by Barrios et al. *Circulation*. 120: E32, 2009.
20. Wright JT, Probstfield JL, Cushman WC, Pressel S, Cutler JA, **Davis BR**, Einhorn PT, Rahman, M, Whelton PK, Ford CE, Haywood LJ, Margolis KL, Oparil S, Black HR,

- Alderman MH, for the ALLHAT Collaborative Research Group. Response to Letter by Onguibo et al. *Archives of Internal Medicine*, 169:1810, 2009.
21. Margolis KL, Davis BR, Baimbridge C, et al. Author Response to Lipid-Lowering in African Americans in ALLHAT—Optimism Bias? *Journal of Clinical Hypertension* 15 (12), 941, 2013.
 22. Einhorn PT, Whelton PK, **Davis BR**, Wright JT, Cushman WC, Zieman SJ for the ALLHAT Collaborative Research Group. Real world evidence supports optimally dosed thiazide-type diuretics as preferred in treatment regimens of older hypertensives. *Journal of the American Geriatric Society*.63:1045-1047. 2015.

ABSTRACTS:

1. **Davis BR**, Friedman LM, Lichstein E: The prognostic value of the duration of the ambulatory electrocardiogram. *Circulation* 70(4):II-267, 1984.
2. **Davis BR**, Langford HG, Blaufox MD, Polk BF, Shulman NB, Curb JD: The association of standing blood pressure and mortality in hypertensives. *Circulation* 70(4):II-359, 1984.
3. **Davis BR**, Langford HG, Blaufox MD, Curb JD, Polk BF, Shulman NB: Postural hypotension in a hypertensive population. *Circulation* 71:415A, 1985.
4. **Davis BR**, Curb JD, Borhani NO, Prineas R, Molteni A: Coffee and serum cholesterol in the HDFP. *CVD Epidemiology Newsletter* 37:48, 1985.
5. **Davis BR**, Furberg CD, Williams CB: The natural history of specific complaints in post-myocardial infarction patients. *CVD Epidemiology Newsletter* 37:51, 1985.
6. Curb JD, **Davis BR**, Tung B: Standardized physician preparation of death certificates. *Controlled Clinical Trials* 6:237, 1985.
7. **Davis BR**, Furberg CD, Williams CB: Survival analysis of adverse effects data in the BHAT. *Controlled Clinical Trials* 6:220-221, 1985.
8. **Davis BR**, Langford HG, Oberman A, Shulman N, Wassertheil-Smoller S: Isolated diastolic hypertension in the Hypertension Detection and Follow-up Program. *CVD Epidemiology Newsletter* 39:19, 1986.
9. Hardy RJ, **Davis BR**, Tung B: The Multicenter Trial of Cryotherapy for Retinopathy of Prematurity: Design features. *Controlled Clinical Trials* 7:235, 1986.
10. **Davis BR**, Hawkins CM, Blaufox MD, Langford HG, Oberman A, Swencionis C, Wassertheil-Smoller S, Wylie-Rosett J, Zimbaldi N: Trial of Antihypertensive Interventions and Management: Design features. *Controlled Clinical Trials* 8:285-286, 1987.
11. **Davis BR** and Hardy RJ: Stopping rule versus conditional power. *Controlled Clinical Trials* 9:246, 1988.
12. Moyé LA on behalf of the SAVE Investigators: Rationale and design of a randomized clinical trial on postinfarction survival and ventricular enlargement. *Controlled Clinical Trials* 10:329-330, 1989.
13. Hardy RJ, **Davis BR**, Tung B, Palmer EA: Statistical considerations in the early termination of the Multicenter Trial of Cryotherapy for Retinopathy of Prematurity. *Controlled Clinical Trials* 10:320, 1989.

14. Palmer EA, Hardy RJ, Flynn JT, Phelps DL, Schaffer DB, **Davis BR**, Mowery R, Tung B, Phillips C: Operational aspects of the early termination of the Multicenter Trial of Cryotherapy for Retinopathy of Prematurity. *Controlled Clinical Trials* 10:320-321, 1989.
15. **Davis BR** and Hardy RJ: Stochastic curtailment methods and confidence intervals. *Controlled Clinical Trials* 10:321, 1989.
16. Wittes J, **Davis BR**, Berge KG, Cohen J, Grimm R, Hawkins CM, Kuller LH: Plans for analysis of the SHEP trial. *Controlled Clinical Trials* 11:267, 1990.
17. **Davis BR**, Oberman A, Blafox MD, Smoller SW, Langford HG, Zimbaldi N, Hawkins CM, Cutler J: Continuation of the Trial of Antihypertensive Interventions and Management: Design features. *Controlled Clinical Trials* 11:274-275, 1990.
18. **Davis BR**, Blafox MD, Oberman A, Langford HG, Smoller SW, Zimbaldi N Hawkins CM, Cutler J: The Trial of Antihypertensive Interventions and Management: 6 month change in diastolic blood pressure by race-sex and age. *Circulation* 83:716, 1991.
19. Ford CE, **Davis BR**, Hawkins CM, Stamler J, Langford HG, Daugherty SA, Borhani NO, Curb JD, Payne GH, Remington RD: The effect of treatment on combined trial endpoints in the Hypertension Detection and Follow-up Program (HDFP). *Circulation* 83:716, 1991.
20. The TAIM Research Group: Long-term drug and weight loss treatment of mild hypertension: Final results of the Trial of Antihypertensive Interventions and Management. *Circulation* 85:868, 1992.
21. **Davis BR**, Wittes J, Pressel S, Berge KG, Hawkins CM, Lakatos E, Moye LA, Probstfield JL: Statistical considerations in the monitoring of the Systolic Hypertension in the Elderly Program. *Controlled Clinical Trials* 13:414, 1992.
22. Packer M, **Davis BR**, Hamm P et al.: Effect of captopril on cause-specific mortality in patients with left ventricular dysfunction after acute myocardial infarction: Results of the SAVE trial. *Circulation Supp* 86(4):I-250, 1992.
23. **Davis BR**, Blafox MD, Oberman A, Wassertheil-Smoller S, Zimbaldi N, Kirchner K, Langford HG: Long-term drug and low sodium/high potassium treatment of mild hypertension: Final results of the Trial of Antihypertensive Interventions and Management. *Circulation* 87(2):3, 1993.
24. The SHEP Cooperative Research Group: Baseline risk factors and incidence of cardiovascular events in older Americans: Results of the Systolic Hypertension in the Elderly Program (SHEP). *Circulation* 87(2):3, 1993.
25. Frost PH, **Davis BR**, Burlando AJ, Camel G, Chiappini M, Curb JD, Guthrie GP, Isaacson J, Smoller SW, Stamler J, Wilson A: Risk factors for coronary heart disease in persons with isolated systolic hypertension: Findings from the Systolic Hypertension in the Elderly Program. *Circulation* 88(4,2):I-612 1993.
26. Frost PH, **Davis BR**, Burlando AJ, Camel G, Chiappini M, Curb JD, Guthrie GP, Isaacson J, Smoller SW, Stamler J, Wilson A: Serum lipids and coronary heart disease in persons with isolated systolic hypertension. *Circulation* 88(4,2):I-612 1993.
27. **Davis BR**, Vogt T, Frost PH, Burlando AJ, Cohen J, Wilson A, Brass L, Frishman W, Price T, Stamler J: Risk factors for cerebrovascular disease in persons with isolated

- systolic hypertension: Findings from the Systolic Hypertension in the Elderly Program. *Circulation* 88(4,2):I-169 1993.
28. The Systolic Hypertension in the Elderly Program Cooperative Group: Low dose diuretic-based antihypertensive treatment reduces risk in elderly diabetics with isolated systolic hypertension. *Circulation* 88(4,2):I-386 1993.
 29. **Davis BR**, Wassertheil-Smoller S, Oberman A, Blafox MD, Zimbaldi N, Kirchner K, Wylie-Rosett J. Dietary treatment of mild hypertension - Are the less obese more likely to remain off drugs? *Circulation* 89(2):4, 1994.
 30. Wassertheil-Smoller S. for the SHEP Cooperative Research Group. Change in depression as a precursor of cardiovascular events. *Circulation* 89(2):6, 1994.
 31. Moye LA, **Davis BR**, Hawkins CM, Sacks F, Pfeffer MA, Cole T, Brown L, Crawford B: Decision rules for predicting lipid values in a cholesterol reduction clinical trial. *Controlled Clinical Trials* 15(3S):74S, 1994.
 32. **Davis BR** for the ALLHAT Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial : Design features. *Controlled Clinical Trials* 16(3S):47S, 1995.
 33. Egan DA, Pressel S, **Davis B** on behalf of the ALLHAT Research Group. Recruitment success by type of site in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) Vanguard. *Controlled Clinical Trials* 16(3S):106S, 1995.
 34. Pressel S, Egan DA Ford C, et al. on behalf of the ALLHAT Research Group. Selection of clinical sites for the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). *Controlled Clinical Trials* 16(3S):106S, 1995.
 35. Cushman WC, for the ALLHAT Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT): Design and initial characteristics. *Hypertension* 15:1356, 1995.
 36. **Davis BR** for the ALLHAT Research Group - Operational perspectives in the conduct of large multicenter clinical trials. *Controlled Clinical Trials* 16(3S):14S, 1995.
 37. Kostis JB, **Davis BR**, Grimm RH, et al. Prevention of heart failure by antihypertensive drug treatment in older persons with isolated systolic hypertension. *Circulation*, 94(8), I-214, 1996.
 38. Roberts R, Fromm R, Beudreau A et al. Multi-center blinded trial utilizing multiple diagnostic markers to exclude myocardial infarction in patients presenting consecutively to the ER with chest pain. *Circulation* 94(8), I-322, 1996.
 39. Sacks FM, Wun CC, Cole TG et al. The influence of baseline lipids on reduction in coronary events by pravastatin: Cholesterol and Recurrent Events Trial. *Circulation* 94(8), I-539, 1996.
 40. Grimm RH, **Davis BR**, Whelton P et al. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT): Update on recruitment and baseline characteristics. *Am J Hypertension* 9 (Part II): 26A, 1996.
 41. Grimm RH, **Davis BR**, Whelton P et al. Patient recruitment experience in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). *J Hypertension* (Suppl 1):998, 1996.
 42. Barzilay J, Jordan J, Grimm RH, et al. and the ALLHAT Investigators. Characteristics of the diabetic cohort in the ALLHAT study. *Hypertension* 10: 86A, 1997.

43. Sacks FM, Moye LA, **Davis BR**, et al. The influence on coronary events of lipid therapy during treatment with pravastatin: The CARE trial. *Circulation* 96(8):I66, 1997.
44. Grimm RH, **Davis BR**, Alderman MA et al. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT): The largest hypertension trial ever undertaken: Baseline characteristics. *Circulation* 96(8):I278, 1997.
45. Arnold JMO, **Davis BR**, Nash DT, et al. Influence of patient adherence to treatment by pill count and clinical outcomes in the Cholesterol and Recurrent Events (CARE) Study. *Circulation* 98(17):4258, 1998.
46. Arnold JMO, **Davis BR**, Nash DT, et al. Lipid levels, adherence to medication, baseline characteristics in the Cholesterol and Recurrent Events (CARE) Study. *Journal of American College of Cardiology*, 31(2):A89, 1998.
47. Plehn JF, Rouleau JL, Pfeffer Ma, **Davis BR**, et al. Reduction of stroke incidence following myocardial infarction with pravastatin. *Stroke*. 29(1):70, 1998.
48. Nwachuku CE, Cutler JA, Payne GH, Proschan MA, Ford CE, **Davis BR**. Regional differences in attainment of blood pressure among treated hypertensive patients in the United States. *Journal of Hypertension*, 16(S2):796, 1998.
49. Pressel S, Morvillo C, Kimmel B, **Davis B** et al. Patient recruitment in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) *Controlled Clinical Trials* 19(3S):46S, 1998.
50. Thompson J, **Davis BR**. A simulation study of the effects of small center enrollment in multi-center clinical trials. *Controlled Clinical Trials* 19(3S):53S, 1998.
51. **Davis BR**, Pressel S, Wright J, et al. Clinical center recruitment experience in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) *Controlled Clinical Trials* 21(2S):63S, 2000.
52. Piller L, **Davis B**, Kimmel B, et al. The ascertainment of endpoints by primary care practitioners in a long-term clinical trial. *Controlled Clinical Trials* 21(2S):104S, 2000.
53. Piller LB, **Davis BR**, Cutler JA, et al. Validation of heart failure events in ALLHAT participants in assigned to doxazosin. *AJH* 14(4) Part 2:180A, 2001.
54. **Davis BR**. Closeout procedures for clinical trials. *Controlled Clinical Trials* 22(2S):22S, 2001.
55. Pressel S., **Davis B**, Babiak-Vasquez, et al. Follow-up specialists in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) *Controlled Clinical Trials* 23(2S):48S, 2002.
56. **Davis BR**, Pressel S, Ford CE, et al. The ALLHAT Clinical Trials Center – Expected and Unexpected Challenges. *Controlled Clinical Trials* 23(2S):56S, 2002.
57. Pressel S, **Davis B**, Ford C, et al. Closeout procedures in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) *Controlled Clinical Trials* 23(2S):57S, 2002.
58. Piller L, Simpson L, **Davis B**, et al. The review of event reports in ALLHAT. *Controlled Clinical Trials* 23(2S):77S, 2002.
59. Simpson L, Pressel S, Piller L, Bettencourt J, DeLeon B, **Davis B**. Ascertainment of vital status using outside databases in ALLHAT. *Controlled Clinical Trials* 23(2S):76S, 2002.
60. Holmes DR, Savage M, LaBlanche JM et al. Results of prevention of restenosis with

- tranilast and its outcomes- (PRESTO) trial. *Circulation* 106 (10): 1243-1250, 2002.
61. **Davis BR**, Cutler JA, Furberg CD, Wright JT, Farber MA. Relationship of antihypertensive treatment regimens and blood pressure change with risk of heart failure in hypertensive patients randomized to doxazosin or chlorthalidone: Further analyses from ALLHAT J of Hypertension 20: S161, 2002.
 62. Cushman WC, Ford CE, Cutler JA, Margolis KL, **Davis BR**, Grimm RH. Blood pressure control in the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). *Circulation* 106 (19): 476 2355 Suppl. S, 2002.
 63. Best PJM, Berger PB, Grannett JR, **Davis BR**, Willerson JT, Holmes DR Restenosis is not increased in mild or moderate chronic kidney disease: Results from the PRESTO trial JACC (6): 24A Suppl. A, 2003.
 64. **Davis BR**, Ford C, Pressel S, Dunn K, Piller L. Sensitivity analyses to account for losses to follow-up in the the Antihypertensive and Lipid-Lowering Treatment Trial to Prevent Heart Attack Trial. . *Controlled Clinical Trials* 24(3S):76S, 2003.
 65. Pressel S, **Davis B**, Blanton J. Follow-up specialists in the Antihypertensive and Lipid-Lowering Treatment Trial to Prevent Heart Attack Trial (ALLHAT) – Contribution to Study Closeout. *Controlled Clinical Trials* 24(3S):116S, 2003.
 66. DeLeon B, Piller L, Pressel S, Simpson L, Bettencourt J, **Davis B**. Validation of secondary outcomes – A case study from the Antihypertensive and Lipid-Lowering Treatment Trial to Prevent Heart Attack Trial. *Controlled Clinical Trials* 24(3S):186S, 2003.
 67. Einhorn P, **Davis B**, Piller L, et al. Review of heart failure events in the antihypertensive and lipid lowering treatment to prevent heart attack trial (ALLHAT): ALLHAT heart failure validation study *Circulation* 108 (17): S399-400, 2003.
 68. Kao J, Tobis J, McClellan RL, Heaton MR, **Davis BR**, Holmes DR, Currier JW Metformin treatment is associated with decreased clinical events in diabetic patients undergoing percutaneous intervention: A PRESTO substudy. *Circulation* 108(17): S568, 2003.
 69. Rahman M, Barzilay J, Batuman V, **Davis B**, et al. Incidence of end stage renal disease (ESRD) and cardiovascular disease (CVD) in high risk hypertensive patients with reduced glomerular filtration rate (GFR). *Journal of the American Society of Nephrology* 4:674A- 674A, Suppl, 2003.
 70. **Davis B**. Heart failure results in the antihypertensive and lipid-lowering treatment to prevent heart attack trial. *European Heart Journal* 25:122-122, Suppl, 2004.
 71. Grimm R, **Davis B**, Piller L, et al. Did type of prior antihypertensive therapy influence the heart failure results in ALLHAT? *Journal Of Hypertension* 22:S151-S151, 2004. PMID: PMC2788785
 72. Barzilay JI, Pressel S, **Davis BR**, et al. Risk and impact of incident glucose disorders in hypertensive older adults treated with an ace inhibitor, a diuretic, or a calcium channel blocker: A report from the ALLHAT trial. *American J of Hypertension* 17(5):1A, 2004.
 73. Einhorn PT, **Davis BR**, Piller LB, et al. The antihypertensive and lipid lowering treatment to prevent heart attack trial (ALLHAT) heart failure (HF) validation study:

- Clinical presentation of hospitalized HF events and subsequent mortality rates. *Circulation* 110 (17):731,Suppl, 2004.
74. **Davis BR**, Black HR. Clinical outcomes in participants with cardiovascular dysmetabolic syndrome in the antihypertensive and lipid-lowering treatment to prevent heart attack trial. *Circulation* 110(17):796, Suppl, 2004.
 75. Oparil S, **Davis BR**, Nwachuku C, Pressel S, deLeon B. Stroke results in the antihypertensive and lipid-lowering treatment to prevent heart attack trial. *Stroke* 35(1):235, 2004.
 76. Cushman WC, Ford CE, Einhorn P, Wright JT, Preston RA, **Davis BR**, Basile JN Blood pressure control by randomized drug group in ALLHAT *Am J Hyperten* 17(5):30A, 2004. PMID: PMC2897821
 77. Cutler JA, Piller LB, Pressel S, Graumlich JF, Hamilton BP, Parish DC, Qureshi N, Randall OS, **Davis BR** Results of monotherapy in ALLHAT: On-treatment analyses. *Am J Hyperten* 17(5):30A-31A , 2004.
 78. Whelton, PK, Barzilay J, Cushman WC, **Davis BR**, Iiamathi E, Kostis JB, Leenen FHH, Louis GT, Margolis K, Mathis DE, Moloo J, Nwachuku C, Panebianco D, Parish DC, Pressel S, Simmons DL, Thadani U. Clinical outcomes in ALLHAT antihypertensive trial participants with type 2 diabetes, impaired fasting glucose, and normoglycemia. *Southern Medical Journal* 97 (Supplement 1):6, 2004.
 79. **Davis BR**, Pressel S. Can blood pressure lowering prevent cognitive decline - Evidence from the SHEP trial. *Journal of the Neurological Sciences* 229:343,(Sp. Iss), 2005.
 80. Oparil S, **Davis B**, Nwachuku C, et al. Stroke results in the antihypertensive and lipid lowering treatment to prevent heart attack trial. *Circulation* 112 (17):U475, Suppl, 2005.
 81. Leenen F, Nwachuku C, Cushman W, Black H Simpson L, **Davis B**. Cardiovascular outcomes in hypertensives with coronary artery disease randomized to amlodipine versus lisinopril in the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). *Journal of Hypertension* 23: S21-S22, Suppl, 2005.
 82. Leenen F, Nwachuku C, Cushman W, Black H Simpson L, **Davis B**. Outcomes in high risk hypertensives randomized to calcium channel blocker versus angiotensin converting enzyme inhibitor in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). *Journal of Hypertension* 23:S113, Suppl, 2005.
 83. Black H, **Davis B**. Clinical outcomes in participants with cardiovascular dysmetabolic syndrome in the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). *Journal of Hypertension* 23: S146, Suppl, 2005.
 84. **Davis B**. Absence of an interaction between the alpha-adducin polymorphism and anti-hypertensive treatment on cardiovascular risk in high-risk hypertensives: The GenHAT study. *Journal of Hypertension* 23: S272, Suppl, 2005. PMID: PMC2766552
 85. Arnett D, **Davis B**, Ford C, et al. Absence of an interaction between the ace insertion-deletion polymorphism and ace inhibitor versus other antihypertensive treatments on cardiovascular risk in high-risk hypertensives: The GenHAT study. *American Journal Of Hypertension* 18(5):4A, Suppl,2005.

86. Leenen F, Nwachuku C, Cushman W, Black H Simpson L, **Davis B**. Outcomes in high risk hypertensives randomized to CCB vs ACE inhibitor in ALLHAT. *American Journal of Hypertension* 18(5):7A, Suppl, 2005.
87. Piller L, Ford C, **Davis B**, et al. Angioedema in the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). *American Journal of Hypertension* 18 (5): 92A, Suppl, 2005.
88. Wright JT, **Davis BR**, Black HR. Clinical outcomes by race in nondiabetic participants with cardiovascular metabolic syndrome in the anti hypertensive and lipid-lowering treatment to prevent heart attack trial. *Ethnicity & Disease* 16(3):S42,2006.
89. Heidenreich PA, **Davis BR**, Furberg CD, et al. Cost-effectiveness of chlorthalidone, amlodipine, and lisinopril as first-line treatment for patients with hypertension: An ALLHAT analysis. *Journal of the American College Of Cardiology* 47(4):372A, Suppl, 2006.
90. Maitland-van der Zee AH, Boerwinkle E, Arnett DK, **Davis BR**. Absence of an interaction between the angiotensin converting enzyme (ACE) insertion-deletion polymorphism and pravastatin on cardiovascular disease in high-risk hypertensives: The GenHAT study. *Pharmacoepidemiology and Drug Safety* 15: S19 Suppl. 1, 2006.
91. **Davis BR**, Simpson LM, Black HR, et al. Heart failure with preserved and impaired left ventricular systolic function in the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT) *Circulation* 114: 571 Suppl. S, 2006.
92. Katz L, Bartholomew L, Dawson G, **Davis BR** et al. Disseminating clinical trial results to promote public health: Case study from the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT) *Journal of General Internal Medicine* 21: 193 Suppl. 4, 2006.
93. Grimm R, **Davis BR**, Cutler JA, et al. Did blood pressure medication withdrawal prior to randomization influence subsequent rates of heart failure in the antihypertensive and lipid- lowering treatment to prevent heart attack trial? *Journal of the American College of Cardiology* 49: 350A: Suppl. A, 2007.
94. Wright JT, **Davis BR**, Haywood J, Einhorn P. Clinical outcomes by race in participants with the metabolic syndrome in the anti hypertensive and lipid-lowering treatment to prevent heart attack trial on doxazosin vs chlorthalidone. *Ethnicity and Disease* 17(3): S31, 2007.
95. Pressel S, **Davis BR**, Ford CE, Piller LB, Simpson LM, Baraniuk S. The Utility of Post-Trial Follow-Up of Participants – The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial Experience. *Clin Trials* 7(4): 468, 2010.
96. JL Probstfield, WC Cushman, **BR Davis**, S Pressel, JA Cutler, P Einhorn, C Ford, S Oparil, P Whelton, JT Wright Mortality and morbidity during and after the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT).. *European Heart Journal* 31, 321-321, 2010.
97. JB Kostis, J Cabrera, JQ Cheng, NM Cosgrove, Y Deng, SL Pressel, **BR Davis** Effect of chlorthalidone treatment on mortality: 20-year follow-up of the systolic hypertension in the elderly program (SHEP). *European Heart Journal* 32, 971-972, 2011.
98. JW Graves, E Reisin, SL Pressel, JM Yamal, **BR Davis**, ALLHAT Collaborative

- Research Group Cardiovascular Outcomes Using Lisinopril or Amlodipine Versus Chlorthalidone in Normal Weight, Overweight, and Obese Hypertensive Patients in the ALLHAT Study *Journal of Hypertension* 30, e141 2012.
99. WJ Kostis, J Cabrera, FH Messerli, JQ Cheng, NM Cosgrove, Y Deng, Sara L Pressel, **Barry R Davis**, John B Kostis. The Systolic Hypertension in the Elderly Program: Competing Cardiovascular and Non-Cardiovascular Risk and Increased Longevity. *Circulation* 126 (21) 2012.
 100. JB Kostis, JE Sedjro, J Cabrera, NM Cosgrove, S Pressel, **BR Davis**. Visit-to-visit variability of systolic blood pressure predicts outcomes mainly in the active treatment group rather than the placebo group in the systolic hypertension in the elderly program: pathophysiologic implications. *Journal of the American College of Cardiology* 61 (10_S) 2013
 101. K Broglio, J Ishak, D Mullins, J Connor, B Luce, **B Davis**. Advantages of Bayesian Adaptive Trials for Comparative Effectiveness Research: Re-adapting ALLHAT. *Value in Health*, Volume 16, Issue 3, Pages A5, 2013.
 102. A Cohen, B Aygun, H Imran, L Luchtman-Jones, AA Thompson, B Fuh, **Barry R Davis**, Sara L Pressel, William Herbert Schultz, Russell E Ware. Extrahepatic Iron Deposition In Chronically Transfused Children With Sick Cell Anemia—Baseline Findings From The Twitch Trial. *Blood* 122 (21), 2238-2238, 2013
 103. 103 ZR Rogers, I Odame, J Kwiatkowski, M Lee, WC Owen, A Cohen, . William C Owen, Alan Cohen, Timothy St Pierre, **Barry R Davis**, Crystal Parker, William Herbert Schultz, Russell E Ware. Liver Iron Concentration By MRI In Chronically Transfused Children With Sick Cell Anemia In The Twitch Trial. *Blood* 122 (21), 780-780, 2013.
 104. JC Wood, A Cohen, B Aygun, H Imran, L Luchtman-Jones, AA Thompson Beng Fuh, **Barry R Davis**, Sara L Pressel, William Herbert Schultz, Russell E Ware. Extrahepatic iron deposition in chronically transfused children with sickle cell anemia—baseline findings from the TWITCH trial. *Blood* 122 (21), 2238-2238, 2013.
 105. P Muntner, J Whittle, AI Lynch, LM Simpson, P Einhorn, EB Levitan, Paul K Whelton, William C Cushman, Gail Louis, **Barry R Davis**, Suzanne Oparil. Visit-to-visit variability of blood pressure and coronary heart disease, stroke, heart failure and mortality: results from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). *Journal of the American Society of Hypertension* 8 (4), e13-e14 2014
 106. M Alderman, C Ford, **B Davis**, S Baraniuk, P Einhorn, J Haywood, S Oparil Linda Piller, Tamrat Retta, ALLHAT Collaborative Research Group. Should antihypertensive treatment recommendation differ for patients with and without coronary heart disease? report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). *Journal of the American Society of Hypertension* 8 (4), e72-e73, 2014
 107. P Muntner, **BR Davis**, WC Cushman, S Bangalore, DA Calhoun, S Pressel, .. Henry R Black, John B Kostis, Jeff Probstfield, Paul K Whelton, Mahboob Rahman, ALLHAT Collaborative Research Group. Treatment resistant hypertension and the incidence of cardiovascular disease and end-stage renal disease: results from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) *Journal of the American Society of Hypertension* 8 (4), e89-e89, 2014

108. JB Kostis, JE Sedjro, WJ Kostis, J Cabrera, SL Pressel, NM Cosgrove, **Barry R Davis**. Visit to visit variability of the orthostatic response of systolic blood pressure is associated with increased risk of morbid and mortal events. *Journal of the American Society of Hypertension* 8 (4), e74-e74, 2014.
109. P Einhorn, R Shah, S Abbasi, JM Yamal, **B Davis**, J Barzilay, A Goldfine ALLHAT Collaborative Research Group. Impaired fasting glucose and body mass index as determinants of diabetes and mortality in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT): is the obesity paradox real? *Journal of the American Society of Hypertension* 8 (4), e120-e121, 2014.
110. M Lee, M Bonner, O Alvarez, L Hilliard, J Rothman, B Mueller, I Osunkwo, Sara Pressel, **Barry Davis**, Russell Ware. Neurocognitive functioning and health-related quality of life of children with sickle-cell disease on chronic transfusion for abnormal transcranial doppler ultrasonography: baseline results from the ted with transfusions changing to hydroxyurea (TWITCH) trial. *Pediatric Blood & Cancer* 61, S92-S92, 2014.
111. L Kaasenbrood, NR Poulter, PS Sever, H Colhoun, SJ Livingstone, SL Pressel, **BR Davis**, Y van der Graaf, SM Boekholdt, FL Visseren. Statin Therapy in Patients With Type 2 Diabetes: Development and Validation of a Model to Predict Individualized Treatment Effects Based on the ASCOT, ALLHAT and CARDS Trials. *Circulation* 130 (Suppl 2), A11552-A11552.
112. Abdul-Rahim AH, Ali M, Fitzmaurice DA, Lip GYH, Mant J, **Davis BR**, Waldo AL, Berry C, McMurray JJV, Petrie JR, Sattar N, Lowe GD, Herz M, Lees KR, for the VICCTA Steering Committee, Advancing knowledge by optimising use of existing data: VICCTA Collaboration. Presented at International Stroke Conference, San Diego, CA 2014.

INVITED PRESENTATIONS – SELECTED SAMPLE

1. American Statistical Association
A distributed data processing system in a multicenter clinical trial
Las Vegas, Nevada, August, 1985
2. The Drug Information Association Workshop on Clinical Data Management--The State of the
Art Remote data entry from a coordinating center perspective: The SHEP experience
Philadelphia, Pennsylvania, September, 1985
3. Research Seminar in Probability and Pattern Theory, Brown University
Theory and practice of clinical trials
Providence, Rhode Island, November, 1985
4. National Heart, Lung, and Blood Institute
The value of duration of the ambulatory ECG: A decision analysis approach
Bethesda, Maryland, September, 1986
5. The Drug Information Association
Hardware and software considerations for the management of large clinical trials
San Francisco, California, June, 1987

6. Houston Area Chapter of the American Statistical Association
Modeling the AIDS epidemic
Houston, Texas, February, 1988
7. Medical Grand Rounds, Baylor College of Medicine
Modeling the AIDS epidemic
Houston, Texas, April, 1988
8. Annual Conference of Texas Statisticians
Short-term projections of AIDS incidence in Texas
Houston, Texas, March, 1990
9. Department of Veterans' Affairs Cooperative Studies Program
Biostatisticians' and Pharmacists' Meeting
Sequential Monitoring
Toronto, Ontario, Canada, May, 1990
10. Houston Area Chapter of the American Statistical Association
Operational and statistical issues in a clinical trials coordinating center
Houston, Texas, December, 1990
11. American Society for Hypertension
Is there a J-shape phenomenon in the treatment of isolated systolic hypertension?
New York, New York, May, 1992
12. International Society of Hypertension in Blacks
Long-term results by race for diet and drug therapy of hypertension
Atlanta, Georgia, May, 1992
13. Icelandic Congress for Cardiology/Internal Medicine
Results on the Survival and Ventricular Enlargement (SAVE) Trial
Egilstadir, Iceland, June, 1992
14. Department of Public Health, University of Sydney
The Systolic Hypertension in the Elderly Program (SHEP): Final results
Sydney, Australia, December, 1992
15. National Medical Association
Clinical trials design: Monitoring and analysis
Orlando, Florida, July, 1994
16. Memorial Session for Richard D. Remington - American Statistical Association
Stochastic curtailment methods
Toronto, Ontario, Canada, August, 1994
17. Society for Clinical Trials
Equal risk for equal measures?
Pittsburgh, Pennsylvania, May, 1996
18. Finnish Society of Hypertension

- The Systolic Hypertension in the Elderly Program – Results by Diabetes Status
Helsinki, Finland, May, 1996
19. International Symposium on Hypertension in the Community: Screening, Investigation, and Therapy. ALLHAT: The largest clinical trial in hypertension ever conducted
Geneva, Switzerland, February, 1998
 20. NIH Workshop on Research Needs for the Design and Analysis of Surrogate Endpoints in Clinical Trials Equal risk for equal measures?
Cardiovascular disease, blood pressure, and lipids.
Potomac, Maryland, December, 1998
 21. American College of Cardiology
The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT): Interim Results .
Anaheim, California, March, 2000
 22. University of Texas Medical School Grand Rounds
The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)
Houston, Texas, March, 2001
 23. Uncontrolled Systolic Hypertension Symposium – American Journal of Cardiology
The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)
Washington, D.C., April, 2002
 24. Chilean Society of Internal Medicine
Heart failure in Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial
Santiago, Chile, October, 2003
 25. American Society of Hypertension
Diuretics versus ACE inhibitors and calcium channel blockers for the prevention of heart failure
New York, New York, May, 2004
 26. Washington University, Department of Biostatistics
Gene-treatment interactions -Genetics of Hypertension Associated Treatment (GenHAT) Study
St. Louis, Missouri, April, 2005
 27. Blood Pressure Lowering Treatment Trialists' Collaboration - Heart failure in Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial
Milan, Italy, June, 2005
 28. Spinal Cord Injury Trials Workshop – Methodist Hospital Neurological Institute
Phase II trials design
Houston, Texas, January, 2006

29. American Society of Hypertension
Metabolic consequences of hypertension treatment
New York, New York, May 2006
30. American Statistical Association
Are megatrials worth it?
Seattle, Washington, August, 2006
31. Workshop sponsored by Centers for Disease Control and Prevention, National Cancer Institute, National Human Genome Research Institute and National Heart, Lung and Blood Institute. Personal Genomics: Establishing the scientific foundation for using personal genome profiles for risk assessment, health promotion and disease prevention. Scientific evaluation of the impact of interventions associated with genetic risk factor information.
Bethesda, Maryland, USA December, 2008
32. NHLBI – DPPS – ALLHAT, Lessons Learned
Bethesda, MD, USA January 2009
33. Institute of Medicine, Committee on Public Health Priorities to Reduce and Control Hypertension in the U.S. Population The Hypertension, Detection, and Follow-up Program (HDFP) and the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)
Washington, DC, USA April 2009.
34. International Chinese Statistical Association – Does it matter how you lower blood pressure?
San Francisco, CA, June, 2009.
35. Joint Statistical Meetings – Panel Discussion on Stopping Boundaries for Harm in Clinical Trials
Washington, DC, August 2009
36. American Heart Association Scientific Sessions – Symposium for ALLHAT- Overview of ALLHAT post-trial follow-up
Orlando, FL November, 2009
37. American Society of Hypertension – Symposium for ALLHAT- Overview of ALLHAT post-trial follow-up
New York, NY May, 2010
38. Case Western Reserve University School of Medicine – Department of Epidemiology and Biostatistics - The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) – Expected and Unexpected Challenges
Cleveland OH June, 2010
39. University of Florida School of Medicine and College of Public Health, Department of Biostatistics – Statistical Issues Arising in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).

Gainesville, FL September 2010

40. Centers for Disease Control – Heart Disease and Stroke Prevention 2010 - Clinical Guidelines Getting to Practice - The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)
Atlanta, GA September 2010
41. International Biometric Conference – Scientific Evaluation of the Impact of Interventions Associated with Genetic Risk Factor Information
Florianopolis, Brazil December 2010
42. University of Kansas Medical Center, Department of Biostatistics – Statistical Issues Arising in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
Kansas City, KS September 2011
43. Baylor College of Medicine, Cardiology Conference - The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) – Expected and Unexpected Challenges
Houston, TX October 2011
44. Duke University School of Medicine - The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) – Expected and Unexpected Challenges
Durham, NC, August 2012
45. 7th Annual Yatsu Symposium, Disparities in Stroke, Memorial Hermann – Texas Medical Center, – Gaps in Knowledge and Future Research Opportunities
Houston, TX, November, 2012
46. Alpha-1 Foundation, Clinical Trial Design for Alpha-1 Antitrypsin Deficiency: A Model for Rare Diseases Pre-Competitive Trial Design.
Bethesda, MD February, 2014
47. American Society of Hypertension. Important Clinical Lessons Learned from Hypertension Trials.
New York, NY, May 2015
48. National Heart, Lung, and Blood Institute Workshop on Research Needs to Improve Hypertension Treatment and Control in African Americans. Multiple Outcomes and Composite Outcomes - What Do They Mean for the Patient? Statistical Aspects.
Bethesda, MD 2015.
49. Tenth Annual Clinical Trials Conference. Current issues regarding data and safety monitoring committees in clinical trials University of Pennsylvania,

Philadelphia, PA April, 2017

50. Duke Industry Statistics Symposium, Duke University, Challenges of a Large Pragmatic Trial.
Duke University, Durham , NC September, 2017

51. Washington University School of Medicine. Challenges of a Large Pragmatic Trial.
St. Louis, MO. June, 2018

52. Florida Atlantic University. Coordinating Clinical Trials.
Boca Raton, FL, September, 2018.

THESIS AND DISSERTATION SUPERVISION

- 1986, Patricia Hogan, M.S.
“Examination of the variability of variable selection with stepwise regression using the bootstrap resampling method”
Current Position: Senior Biostatistician, Wake Forest University School of Medicine, Winston-Salem, NC
- 1989, Shelly Carter, M.S.
“Applications of selected methods for verifying the proportional hazards assumption for Cox regression”
Current Position: Vice President, The Emmes Corporation, Rockville, MD
- 1990, Carolyn Smith, MPH
“Prevalence of musculoskeletal disorders and associated impairment among Mexican-Americans in Southwest United States: NHANES, 1982-1984”
Current Position: Rheumatologist , Dallas, TX
- 1991, Jaye Thompson, M.S.
“Estimating power for Bower's test”
Current Position: Senior Vice-President of Clinical Development and Regulatory Affairs, Opexa Therapeutics
- 1994, Susan Halabi, Ph.D.
“The number and timing of time dependent covariate measurements for the cox regression model”
Current Position: Professor of Biostatistics and Bioinformatics, Duke University.
- 1994, Eva Wlodarczyk, MPH
“Relations between systolic blood pressure and body fatness measures in mildly obese & moderately hypertensive population”

- 1994, Kamal Deka, MPH
“Proposal for development of a protocol for a double blind clinical trial to evaluate the effects of adjuvant therapy in acute otitis media in children”
- 1995, Farzana Maudoodi, MPH
“Development of a Proposal for a Study to Answer the Question: "Are Healthy Full-Term Infants, Born After Intra-Amniotic Infection, at an Increased Risk of Systemic Infection?"
- 1995, Nadeem Mirza, MPH
”Hodgkin's Disease: Correlation of "Favorable" Characteristics with Lymphangiogram and with Laparotomy Findings in Patients with Stage I-II Upper Torso Presentations”
- 1995, Jihong Zong, M.S.“A Rank-Based Method of Selecting a Cutpoint for Continuous Variables in Epidemiological Studies”.
- 1996, Jaye Thompson, Ph.D.
“A Simulation Study of the Effects of Small Center Enrollment in Multi-Center Clinical Trials”.
Current Position: Senior Vice-President of Clinical Development and Regulatory Affairs, Opexa Therapeutics
- 1996, Thomas Fitzsimmons, MPH
“Epidemiology of Eucleation in Dallas, County, 1990-94”.
- 1999, George Rochester, Ph.D.
“Sequential Updating via Dynamic Hierarchical Models: A Bayesian Approach to Longitudinal Data Analysis”.
Current Position: Mathematical Statistician, Food and Drug Administration.
- 1999, Xiangjun Gu, M.S.
“Least-Squares Estimators of Linkage Variance Components for Quantitative Traits in Family Studies”.
- 2001, Dongrui Lu, M.S.
“Bootstrap Approach for Constructing Confidence Interval for 'Change Point Time' in Survival Analysis”.
- 2001, Sarah (MacNeil) Baraniuk, Ph.D.
“Analysis of Interval Censored Events in Hypertension Studies: Evaluation of Treatment of Coronary Heart Disease”.
- 2002, Sharon Eason, MPH

“Asymptomatic Peripheral Arterial Disease Among Caucasian, African American, and Hispanic Men and Women Over 50 Years of Age”.

- 2003, Mike Hernandez, M.S.
“Dealing with Reality: A Review of Methods for Handling Missing Survey Data”
- 2005, Furong Huang, M.S.
“Monte Carlo Simulation for An Improvement On the Kaplan-Meier Estimator of Survival Function”.
- 2006, Allison Ottenbacher, M.S.
“Comparative Study of Goodness-Of- Fit Test Statistics for Ordinal Logistic Regression”.
- 2011, Kristen Andrews, M.S.
“Validity of Using Item Response Theory to Analyze Data from the Work Limitations Questionnaire”
- 2016, Christina Blanchard, M.S.
“Assessing Whether the Number of Predictors Affect the Power of the Hosmer-Lemeshow Test”
- 2017, Arup Sinha, Ph.D.
“Adaptive Group Sequential Designs with Population Enrichment and Endpoint Assessment in Phase 3 Randomized Controlled Trials”
- 2017, Hannah Pervin, Ph.D.
“Auxiliary Covariate Augmentation with Correlated Joint Time-to-Event and Longitudinal Outcomes”
- 2020, Zachary Spigel (M.D.), MPH
“Recurrent Event Modeling in Congenital Heart Disease”